[go: up one dir, main page]

US20200000581A1 - Artificial, flexible valves and methods of fabricating and serially expanding the same - Google Patents

Artificial, flexible valves and methods of fabricating and serially expanding the same Download PDF

Info

Publication number
US20200000581A1
US20200000581A1 US16/563,229 US201916563229A US2020000581A1 US 20200000581 A1 US20200000581 A1 US 20200000581A1 US 201916563229 A US201916563229 A US 201916563229A US 2020000581 A1 US2020000581 A1 US 2020000581A1
Authority
US
United States
Prior art keywords
frame
leaflets
valve
expandable
leaflet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/563,229
Inventor
Henri Justino
Daniel Harrington
Kwonsoo Chun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
William Marsh Rice University
Original Assignee
Baylor College of Medicine
William Marsh Rice University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine, William Marsh Rice University filed Critical Baylor College of Medicine
Priority to US16/563,229 priority Critical patent/US20200000581A1/en
Publication of US20200000581A1 publication Critical patent/US20200000581A1/en
Priority to US17/473,653 priority patent/US11464632B2/en
Priority to US17/478,665 priority patent/US11571300B2/en
Priority to US17/982,232 priority patent/US20230135271A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • A61F2/2418Scaffolds therefor, e.g. support stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2427Devices for manipulating or deploying heart valves during implantation
    • A61F2/243Deployment by mechanical expansion
    • A61F2/2433Deployment by mechanical expansion using balloon catheter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • A61F2/2415Manufacturing methods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0076Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof multilayered, e.g. laminated structures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0008Fixation appliances for connecting prostheses to the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0025Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
    • A61F2220/005Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements using adhesives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0025Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
    • A61F2220/0058Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements soldered or brazed or welded
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0004Rounded shapes, e.g. with rounded corners
    • A61F2230/0008Rounded shapes, e.g. with rounded corners elliptical or oval
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0017Angular shapes
    • A61F2230/0019Angular shapes rectangular
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0028Shapes in the form of latin or greek characters
    • A61F2230/005Rosette-shaped, e.g. star-shaped
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0063Three-dimensional shapes
    • A61F2230/0069Three-dimensional shapes cylindrical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0004Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof adjustable
    • A61F2250/001Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof adjustable for adjusting a diameter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0029Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in bending or flexure capacity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0036Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in thickness
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0037Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in height or in length
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0082Additional features; Implant or prostheses properties not otherwise provided for specially designed for children, e.g. having means for adjusting to their growth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0096Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers
    • A61F2250/0098Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers radio-opaque, e.g. radio-opaque markers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28Materials for coating prostheses
    • A61L27/34Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/507Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels

Definitions

  • Valves exist in the body (e.g., in the heart and the systemic veins) to allow unidirectional blood flow.
  • a variety of congenital conditions, infectious diseases (e.g., rheumatic heart disease), endocarditis, and age-related impairments (e.g., senile stenosis) can necessitate implantation of an artificial valve.
  • an artificial, flexible valve including: a stent defining a wall and a plurality of leaflets extending from the wall of the stent.
  • the plurality of leaflets form a plurality of coaptation regions between two adjacent leaflets.
  • the coaptation regions include extensions along a z-axis and adapted and are configured to form a releasable, but substantially complete seal when the leaflets are in a closed position.
  • the extensions can have a length along the z-axis between about 1 mm and about 10 mm.
  • the extensions can have a curved profile.
  • the curved profile can lie in an x-y plane.
  • the curved profile can be a variance in extension length along the z-axis.
  • the coaptation regions can have a substantially hyperbolic profile.
  • Each of the plurality of leaflets can have a substantially elliptical leaflet-stent attachment line.
  • the stent can be an expandable, cylindrical stent.
  • the leaflets can be reinforced with one or more selected from the group consisting of: reinforcing materials and directional fibers.
  • One or more selected from the group consisting of: coaptation regions and leaflet-stent attachment lines can be reinforced with one or more selected from the group consisting of: additional polymer thickness, reinforcing materials, and directional fibers.
  • Adjacent leaflets can be coupled to a wide post of the stent.
  • the wide post can include one or more windows.
  • the wide post can have a width between about 0.5 mm and about 3 mm.
  • the stent can include metal or plastic.
  • the metal can be selected from the group consisting of: stainless steel, 316L stainless steel, cobalt-chromium alloys, and nickel-titanium alloys.
  • the leaflets can be formed from a first polymer.
  • the first polymer can be selected from the group consisting of: polytetrafluoroethylene, polyethylene, polyurethane, silicone, and copolymers thereof.
  • the stent can be dip-coated in a second polymer.
  • the second polymer can be selected from the group consisting of: polytetrafluoroethylene, polyethylene, polyurethane, silicone, and copolymers thereof.
  • the leaflets can be coupled to the second polymer.
  • the leaflets can be mechanically coupled to the second polymer.
  • the leaflets can be chemically coupled to the second polymer.
  • the leaflets can be coupled to the second polymer by one or more techniques selected from the group consisting of: gluing, chemical fusing, thermal fusing, sonic welding, stitching, and mechanical fastening.
  • a leaflet-stent attachment line for each of the plurality of leaflets can substantially approximate a frame of the stent.
  • the leaflet-stent attachment line can lie within about 3 mm of the frame of the stent.
  • the stent can include one or more anchor points.
  • the anchor points can contain a radio-opaque material.
  • the valve can be adapted and configured for replacement of one or more cardiac valves selected from the group consisting of: aortic, mitral, tricuspid, and pulmonary.
  • the valve can be adapted and configured for insertion in a subject's veins in order to treat venous insufficiency.
  • the valve can be adapted and configured for serial expansion as the subject ages.
  • an artificial, flexible valve including: a stent defining a wall and a plurality of leaflets extending from the wall of the stent. Each of the plurality of leaflets terminates in a commissure line.
  • the commissure lines deviate from a hyperbola formed in the x-y plane by at least one deviation selected from the group consisting of: a deviation in the z-direction and one or more curves relative to the hyperbola.
  • the leaflets can further include extensions beyond the commissure lines along a z-axis.
  • the extensions can have a length along the z-axis between about 1 mm and about 10 mm.
  • the extensions can have a curved profile.
  • the curved profile can lie in an x-y plane.
  • the curved profile can be a variance in extension length along the z-axis.
  • Each of the plurality of leaflets can have a substantially elliptical leaflet-stent attachment line.
  • the stent can have an expandable, cylindrical stent.
  • the leaflets can be reinforced with one or more selected from the group consisting of: reinforcing materials and directional fibers.
  • coaptation regions and leaflet-stent attachment lines can be reinforced with one or more selected from the group consisting of:
  • Adjacent leaflets can be coupled to a wide post of the stent.
  • the wide post can include one or more windows.
  • the wide post can have a width between about 0.5 mm and about 3 mm.
  • the stent can include metal or plastic.
  • the metal can be selected from the group consisting of: stainless steel, 316L stainless steel, cobalt-chromium alloys, and nickel-titanium alloys.
  • the leaflets can be formed from a first polymer.
  • the first polymer can be selected from the group consisting of: polytetrafluoroethylene, polyethylene, polyurethane, silicone, and copolymers thereof.
  • the stent can be dip-coated in a second polymer.
  • the second polymer can be selected from the group consisting of: polytetrafluoroethylene, polyethylene, polyurethane, silicone, and copolymers thereof.
  • the leaflets can be coupled to the second polymer.
  • the leaflets can be mechanically coupled to the second polymer.
  • the leaflets can be chemically coupled to the second polymer.
  • the leaflets can be coupled to the second polymer by one or more techniques selected from the group consisting of: gluing, chemical fusing, thermal fusing, sonic welding, stitching, and mechanical fastening.
  • a leaflet-stent attachment line for each of the plurality of leaflets can substantially approximate a frame of the stent.
  • the leaflet-stent attachment line can lie within about 3 mm of the frame of the stent.
  • the stent can include one or more anchor points.
  • the anchor points can contain a radio-opaque material.
  • the valve can be adapted and configured for replacement of one or more cardiac valves selected from the group consisting of: aortic, mitral, tricuspid, and pulmonary.
  • the valve can be adapted and configured for insertion in a subject's veins in order to treat venous insufficiency.
  • the valve can be adapted and configured for serial expansion as the subject ages.
  • an artificial, flexible valve including: an expandable, cylindrical stent defining a wall and a plurality of leaflets extending from the wall of the stent. Adjacent leaflets can be coupled to a relatively wide post of the stent.
  • the leaflets can further include extensions beyond the commissure lines along a z-axis.
  • the extensions can have a length along the z-axis between about 1 mm and about 10 mm.
  • the extensions can have a curved profile.
  • the curved profile can lie in an x-y plane.
  • the curved profile can be a variance in extension length along the z-axis.
  • the coaptation regions can have a substantially hyperbolic profile.
  • Each of the plurality of leaflets can have a substantially elliptical leaflet-stent attachment line.
  • the leaflets can be reinforced with one or more selected from the group consisting of: reinforcing materials and directional fibers.
  • One or more selected from the group consisting of: coaptation regions and leaflet-stent attachment lines can be reinforced with one or more selected from the group consisting of: additional polymer thickness, reinforcing materials, and directional fibers.
  • the relatively wide post can include one or more windows.
  • the relatively wide post can have a width between about 0.5 mm and about 3 mm.
  • the stent can include metal or plastic.
  • the metal can be selected from the group consisting of: stainless steel, 316L stainless steel, cobalt-chromium alloys, and nickel-titanium alloys.
  • the leaflets can be formed from a first polymer.
  • the first polymer can be selected from the group consisting of: polytetrafluoroethylene, polyethylene, polyurethane, silicone, and copolymers thereof.
  • the stent can be dip-coated in a second polymer.
  • the second polymer can be selected from the group consisting of: polytetrafluoroethylene, polyethylene, polyurethane, silicone, and copolymers thereof.
  • the leaflets can be coupled to the second polymer.
  • the leaflets can be mechanically coupled to the second polymer.
  • the leaflets can be chemically coupled to the second polymer.
  • the leaflets can be coupled to the second polymer by one or more techniques selected from the group consisting of: gluing, chemical fusing, thermal fusing, sonic welding, stitching, and mechanical fastening.
  • a leaflet-stent attachment line for each of the plurality of leaflets can substantially approximate a frame of the stent.
  • the leaflet-stent attachment line can lie within about 3 mm of the frame of the stent.
  • the stent can include one or more anchor points.
  • the anchor points can contain a radio-opaque material.
  • the valve can be adapted and configured for replacement of one or more cardiac valves selected from the group consisting of: aortic, mitral, tricuspid, and pulmonary.
  • the valve can be adapted and configured for insertion in a subject's veins in order to treat venous insufficiency.
  • the valve can be adapted and configured for serial expansion as the subject ages.
  • the valve may not contain any animal-derived materials.
  • a mandrel including: a cylindrical profile and a plurality of recesses adapted and configured to define a plurality of leaflets forming a plurality of coaptation regions between two adjacent leaflets.
  • the coaptation regions can include extensions along a z-axis and be adapted and configured to form a releasable, but substantially complete seal when the leaflets are in a closed position.
  • the mandrel can include one more cutting guides located between the plurality of recesses.
  • the mandrel can include one or more heating elements.
  • a mandrel including: a cylindrical profile and a plurality of recesses adapted and configured to define a plurality of leaflets.
  • Each of the plurality of leaflets terminate in a commissure line.
  • the commissure lines deviate from a hyperbola formed in the x-y plane by at least one deviation selected from the group consisting of: a deviation in the z-direction and one or more curves relative to the hyperbola.
  • the mandrel can include one more cutting guides located between the plurality of recesses.
  • the mandrel can include one or more heating elements.
  • Another aspect of the invention provides a method for fabricating an artificial, flexible valve.
  • the method includes: dip coating a cylindrical mandrel having a plurality of recesses each approximating a profile of a leaflet and coupling the leaflets to an inner wall of a stent.
  • the method can further include dip coating the stent prior to coupling the leaflets to the inner wall of the stent.
  • the stent and the mandrel can have larger diameters than a target location for the valve.
  • the method can further include separating adjacent leaflets from each other.
  • FIGS. 1A and 1B provide perspective (in which fluid flows from the bottom of the stent toward the top of the stent) and top (in which fluid flows out of the page when the valve is open and flows down into the page to close the valve) views of a valve according to an embodiment of the invention
  • FIG. 2 depicts a stent according to an embodiment of the invention
  • FIGS. 3A-3F depict various stent geometries according to embodiments of the invention.
  • FIG. 4 depicts various vertical post geometries according to embodiments of the invention.
  • FIGS. 5A-5D depict the positioning of a leaflet joint adjacent to a window of a vertical post according to an embodiment of the invention
  • FIG. 6 depicts a stent prior to expansion, dip coating, and leaflet installation according to an embodiment of the invention
  • FIG. 7 depicts a stent including one or more anchor points according to an embodiment of the invention.
  • FIG. 8 depicts the engagement of a stent with a holder for dipping and rotation according to an embodiment of the invention
  • FIGS. 9A-9E depict a mandrel according to an embodiment of the invention.
  • FIG. 9F depicts the positioning of a hyperbolic commissure line relative to defined asymptotes according to embodiments of the invention.
  • FIG. 10A depicts a comparison of elliptical vs. parabolic geometries leaflet valley lines according to embodiments of the invention.
  • FIGS. 10B and 10C depict a comparison of elliptical vs. parabolic leaflet stent attachment lines according to embodiments of the invention.
  • FIGS. 11A-11D depict mandrels for forming coaptation regions of varying height according to embodiments of the invention.
  • FIGS. 12A-12D depict mandrels for forming coaptation regions of varying radial length according to embodiments of the invention
  • FIGS. 12E-12H depict mandrels for forming commissure lines having variable depths along the z-axis according to embodiments of the invention
  • FIGS. 121-12K depict mandrels for forming coaptation regions having curved profiles in an x-y plane, resulting in increased coaptation length, according to embodiments of the invention
  • FIGS. 12L-12N depict mandrels for forming commissure lines having curved profiles in an x-y plane, resulting in increased coaptation length, according to embodiments of the invention
  • FIG. 13A depicts a mandrel according to an embodiment of the invention
  • FIGS. 13B and 13C depict the positioning of reinforcing zones on a mandrel according to an embodiment of the invention
  • FIGS. 14A-14C depict various top profiles according to an embodiment of the invention.
  • FIGS. 15A and 15B depict the fabrication of valves according to embodiments of the invention.
  • FIG. 16 depict the fabrication of valves according to an embodiment of the invention.
  • FIGS. 17A and 17B depict the compression of a valve after assembly in order to bring leaflets into contact with each other according to embodiments of the invention
  • FIG. 17C is a high-speed photograph of a closed valve under pressure according to embodiments of the invention.
  • FIG. 18 depicts a method of implanting a valve according to embodiments of the invention.
  • FIG. 19 depicts a method of expanding an implanted valve according to embodiments of the invention.
  • the term “about” is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. “About” can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from context, all numerical values provided herein are modified by the term about.
  • Ranges provided herein are understood to be shorthand for all of the values within the range.
  • a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 (as well as fractions thereof unless the context clearly dictates otherwise).
  • aspects of the invention provide a novel platform that allows development of polymeric valves of any size and shape.
  • aspects of the invention can be applied to valves designed for surgical implantation (e.g., through a sternotomy or thoracotomy) or valves designed for percutaneous, transcatheter implantation. Additionally, embodiments of the invention allow for possible percutaneous replacement of a dysfunctional valve, whether in adults or in small children. In addition, if implanted in a child, embodiments of the invention allow the valve to be serially expanded to accompany the child's growth.
  • Heart valves are currently replaced using tissue valves (homograft or xenograft) or mechanical metal valves, each having their shortcomings. Homograft valves are in short supply, particularly in sizes suitable for use in children, and biologic tissue-based valves (whether bovine, porcine, or homograft) tend to induce an immunologic reaction which leads to failure of these valves. Mechanical valves generally require anticoagulation, and are almost never used in the pulmonary position due to an increased risk of thrombosis.
  • aspects of the invention can be used for venous valve replacement in patients having venous disease such as chronic venous insufficiency (leading to leg swelling). Because the polymer leaflets can be made extremely thin, the valves can even open under extremely low venous pressure gradients.
  • valve 100 provides an artificial, flexible valve 100 .
  • the valve includes an expandable, cylindrical stent 102 defining a wall 104 .
  • Valve 100 further includes a plurality of leaflets 106 a - 106 c .
  • Wall 104 can be formed by dip coating stent 102 in a polymer as further described herein.
  • Leaflets 106 can be coupled to wall 104 along seams 108 using a variety of approaches (e.g., glue) as discussed further herein.
  • Stent 102 can include one or more vertical posts 110 , 112 , which can be relatively narrow posts 110 or relatively wide posts 112 .
  • leaflet joints between adjacent leaflets 106 are positioned on or close to a vertical post 110 , 112 of the stent 102 .
  • valve 100 will now be described in the context of its components and methods of fabrication.
  • stent 102 can be a metallic stent having plurality of wires, strips, and the like 202 defining a plurality of cells 204 , 206 of various sizes.
  • Stent 102 can be fabricated from a variety of malleable materials such as stainless steel, 316L stainless steel, cobalt-chromium alloys, nickel-titanium alloys (colloquially known as “nitinol”), and the like.
  • Stent 102 can also be formed from various non-metallic materials such as plastics such as polyethylene, polyurethane, polytetrafluoroethylene (PTFE), silicone, poly(propylene) (PP), polyethylene terephthalate (PET), and the like.
  • plastics such as polyethylene, polyurethane, polytetrafluoroethylene (PTFE), silicone, poly(propylene) (PP), polyethylene terephthalate (PET), and the like.
  • Stent 102 can be completely enveloped by a polymer dip coating.
  • Stent 102 and/or wall 104 can also be fabricated from a biocompatible material.
  • the stent 102 can be manufactured by laser cutting or wire forming. To increase bonding strength between metal and polymer, roughness of stent surface can be controlled. Some or all open cells 204 , 206 of the stent can be covered as the bare 102 stent is dipped into the polymer solution.
  • FIG. 6 depicts a stent 102 prior to expansion, dip coating, and leaflet installation.
  • Stents 102 typically have a diameter of between about 2 mm and 6 mm prior to expansion and can be expanded to between about 5 mm and about 30 mm for implantation into a subject.
  • the components of stent 102 can have a variety of dimensions that can be selected to achieve a desired flexibility, rigidity, resilience, and the like.
  • the thickness and width of components of the stent 102 can be between about 0.1 mm and about 2 mm.
  • stent 102 can include one or more vertical posts 110 a - 110 c to enhance bonding with leaflets 106 .
  • Stent 102 can include a plurality of vertical posts 110 that can serve a variety of functions. Some vertical posts 110 can include additional structure and are referred to herein as wide posts 112 . Wide posts 112 are preferably located at leaflet joints where two leaflets 106 meet. For example, in a valve 100 having a three leaflets 106 , wide posts 112 can be positioned at 120° intervals within cylindrical stent 102 .
  • Wide posts 112 provide mechanical support to leaflets and prevent or substantially limit inward deformation of wall 104 due to tensile forces applied to leaflets 106 transferred to wall 104 . Without being bound by theory, it is believed that the wide posts 112 provide increased strength and resiliency due to formation of polymer wall 104 through windows 206 and around wide posts 112 , thus providing cohesive holding of the polymer to itself around the stent 102 instead of relying solely on adhesive bonding of the polymer wall 104 to the stent 102 .
  • window 208 can have a width of between about 0.5 mm and about 3 min (e.g., about 1 mm) and a height of between about 1 mm and about 10 mm (e.g., about 5 mm).
  • FIGS. 3A-3F A variety of additional wide post geometries are depicts in FIGS. 3A-3F .
  • the wide posts have a solid architecture without any windows.
  • the wide posts have a substantially rectangular architecture defining a single, long window as in FIGS. 1A, 1B, and 2 .
  • the wide posts define a plurality of coaxial substantially rectangular windows.
  • the wide posts define a plurality of coaxial, substantially parallel windows.
  • FIG. 3E the wide posts define a plurality of coaxial, substantially rectangular windows in a 2 ⁇ 3 arrangement.
  • the wide posts include a plurality of circular windows.
  • any geometry can be utilized including windows having a profile approximating a triangle, a square, an n-gon (e.g., a hexagon, an octagon, and the like), and the like.
  • FIGS. 5A-5D the positioning of a leaflet joint 502 (formed, e.g., on mandrel 900 as discussed herein) adjacent to window 206 of wide post 112 is depicted.
  • the polymer dip-coated wall 104 is completely transparent for case and clarity in viewing, but can be transparent, translucent, or opaque.
  • FIG. 5B-5D further depict how a geometry of the stent 102 can be selected to substantially approximate the leaflet-stent attachment seam 108 discussed herein in order to provide added mechanical support and resiliency.
  • stent 102 can include one or more anchor points 702 .
  • Anchor points 702 advantageously facilitate holding, dipping, and rotation of the stent 102 during the dip coating process without interfering with the dip coating of the remainder of the stent architecture. Accordingly, the entire stent 102 can be dip coated in a single dipping, although multiple dippings can be utilized to control coating density, thickness, and the like.
  • Anchor points 702 can also receive one or more radio-opaque materials such as platinum to aid in placement and visualization of the valve.
  • stent 102 can be engaged with a holder 802 (e.g., by posts 804 ) for dipping and rotation.
  • a holder 802 e.g., by posts 804
  • the polymer e.g., polymer that is wet on the stent 102
  • the stent can be positioned horizontally and rotated axially.
  • Leaflets 106 can be formed using a variety of techniques including dip coating, 3D-printing (also known as additive manufacturing), molding, and the like.
  • leaflets 106 can be fabricated by dip coating a mandrel 900 with a polymer.
  • the mandrel 900 can be made with a solid such as a metal (e.g., stainless steel, titanium, aluminum, and the like), a plastic (e.g., polyethylene, polypropylene, polyvinyl chloride, polytetrafluoroethylene, polyoxymethylene, and the like), and the like. Since the coated polymer leaflets 106 will be removed from the mandrel 900 after the polymer dries, roughness of mandrel surface can be controlled using known machining and other manufacturing techniques.
  • the mandrel 900 can be made from a cylinder.
  • the diameter of the mandrel 900 is a slightly (e.g., between about 0.05 and about 0.4 mm) smaller than inner diameter of stent 102 after expansion.
  • the mandrel 900 for the leaflets 106 can have novel features, including edges representing the leaflet attachment points that are mathematically defined and leaflet tips that are extended in order to increase the coaptation length of the leaflets.
  • the mandrel 900 can be dimensioned to produce leaflets 106 having different regional thickness and supplementary materials such as directional fibers or reinforcing particles inserted between layers or mixed into the polymer solution in order to increase durability. For example, polymer interaction with particles on the nanoscale or microscale can greatly improve the physical properties or tear resistance of the polymer leaflets 106 .
  • Mandrel 900 can be designed to have a complementary geometry to the desired leaflet shape and permits easier viewing of leaflet geometry. Although mandrel 900 is utilized to describe the geometry of the leaflet 106 , it should be recognized that the upstream surface of the resulting leaflets will have this geometry when formed by dip coating and that the complementary geometry of the leaflet(s) 106 can be produced using techniques other than dip coating.
  • Mandrel 900 is preferably cylindrical and can have an outer profile substantially approximating an inner profile of stent 102 .
  • Mandrel 900 can define a plurality of pockets 902 that each define a leaflet 106 as it hangs from wall 104 via attachment line 108 .
  • Each leaflet 106 terminates in a commissure line 904 often, but not necessarily lying in a plane at the point where the elliptical or parabolic curve ends and where the leaflet often contacts the other leaflets.
  • a substantially vertical coaptation region 906 can extend beyond the commissure line 904 to an extended commissure line 912 for improved sealing as will be discussed herein.
  • mandrel can be cast, machined, printed, or otherwise fabricated so that pockets 902 have a desired geometry.
  • the commissure line 904 (and optionally the coaptation region 906 and extended commissure line 912 ) has a substantially hyperbolic profile when viewed in the x-y plane.
  • leaflet-stent attachment line 108 and/or a leaflet valley line 908 (formed by taking a cross-section in a z plane) can have substantially elliptical profiles.
  • elliptical profiles better promote a secure pocket shape and the closure of the leaflet-stent attachment line 108 to the contour of the cylindrical mandrel 900 .
  • a comparison of elliptical vs. parabolic leaflet valley lines is provided in FIG. 10A .
  • a comparison of elliptical vs. parabolic leaflet-stent attachment lines is provided in FIGS. 10B and 10C .
  • mandrel 900 can define a gap 910 between adjacent leaflets.
  • leaflets 106 with a hyperbolic profile can produce smaller gaps than leaflets with parabolic profiles.
  • gaps 910 can be less than 1 mm or between about 0.1 mm and about 1 mm (e.g., between about 0.1 mm and about 0.2 mm, between about 0.2 mm and about 0.3 mm, between about 0.3 mm and about 0.4 mm, between about 0.4 mm and about 0.5 mm, between about 0.5 mm and about 0.6 mm, between about 0.6 mm and about 0.7 mm, between about 0.7 mm and about 0.8 mm, about 0.8 mm and about 0.9 mm, about 0.9 mm and about 1 mm, and the like).
  • the length of hyperbolic commissure line 904 is about twice the radius of the stent or mandrel.
  • the positioning of a hyperbolic commissure line 904 relative to defined asymptotes is depicted in FIG. 9F .
  • coaptation region can have minimal height in the z-axis so as to consist only of the commissure line 904 .
  • coaptation region 906 can have a vertical extension in the z-axis to an extended commissure line 912 as depicted in FIGS. 11B-11D .
  • the height of the coaptation region 906 can be selected to reduce the amount of regurgitation, while still allowing the valve to open.
  • the coaptation region 906 can have a height between about 1 mm and about 10 mm (e.g., about 3 mm).
  • 11B-11D depict extensions of coaptation region 904 that extend solely in the z-axis, the same effect can be achieved using a smooth leaflet-stent attachment line that extends in the z-axis so that the adjacent leaflet-stent attachment lines (and/or the regions of lealets hanging therebetween) approach and/or contact each other to form an extended coaptation region.
  • the zone of coaptation is affected by the pressure placed upon the closed valve 100 .
  • Proper coaptation also allows the leaflets 106 to support each other, so there is less stress placed on any individual leaflet 106 .
  • Another benefit of enhancing height of the coaptation zone is that this allows the valve 100 to be re-dilated to a larger diameter late after implantation (such as to accommodate growth of a pediatric patient), while still maintaining competence of the valve 100 .
  • Options for enhancing the height of the coaptation zone include creating excess length of the leaflet free edges, so that the free edge length is greater than twice the radius of the stent or mandrel depicted in FIG. 9E . Lengthening of the leaflet free edges can be accomplished by curved edges in the x-y plane, or in the z-axis, or in all 3 axes.
  • coaptation regions 906 can have varying heights in the z-axis between the commissure line 904 and extended commissure line 912 .
  • the height of coaptation region 906 can increase toward the outside of the mandrel as depicted in FIG. 12B .
  • the height of the coaptation region 906 can dip to form a trough between the outside and the center of the mandrel 900 as depicted in FIG. 12C .
  • the commissure lines 904 , coaptation regions 906 and/or extended commissure lines 912 can have curved profiles in an x-y plane (as opposed to a substantially hyperbolic profile) in order to increase the length of the commissure line 904 , coaptation region 906 , and/or extended commissure line 912 .
  • the mandrel 900 can be thicker between the perimeter and the center as depicted in FIG. 121 to produce one or more scallops.
  • the mandrel 900 can have either a single curve or multiple curves.
  • the thickness of the leaflets 106 can be controlled regionally. Because the most common failure points are at the outer edges of the leaflets 106 (such as commissure line 904 or extended commissure line 912 and leaflet-stent attachment line 108 ), increased thickness at outer areas of the leaflets 106 can improve the strength and durability. Also, if local areas are expected to have concentrated stress, the areas can be locally reinforced (e.g., made thicker than other areas). The thickness can be smoothly increased.
  • the width of thickened area along leaflet-stent attachment line 108 can be large enough to cover the glued area for bonding the leaflets 106 and the covered stent 102 .
  • the thickness of thickened areas of the leaflets is between about 0.1 mm and about 1 mm.
  • the thickness of the leaflets is between about 0.01 mm and about 0.2 mm.
  • Different reinforcing materials such as strips, fibers and particles can be placed between the layers, or directly mixed into the polymer solution.
  • the inserted material(s) can prevent tearing and reduce propagation of the tear if it occurs.
  • the materials can have directional properties and can be layered onto, or embedded into, the leaflets in an optimal direction to prevent or limit tears.
  • a reinforcing zone 1302 can be formed on the mandrel 900 prior either by removing mandrel material to allow for additional thickness in certain (e.g., outer) regions of leaflets 106 or by introducing one or more reinforcing fibers prior to, during, or after dip coating.
  • Suitable reinforcing materials include fibers (e.g., polymers, nanotubules, aramids, para-aramids, and the like), wires, and the like. Transitions between reinforced and non-reinforced areas can be smooth in order to minimize any turbulence in the implanted valve 100 .
  • the coated polymer After dipping the mandrel 900 into the polymer solution, the coated polymer dries in order to form the leaflet(s) 106 . Because the formed leaflets 106 are connected, they need to be separated from each other. These can be cut by a sharp cutter (e.g., a knife, a scalpel, a razor blade, a utility knife, and the like), a heated iron, a laser, a rotary tool, and the like.
  • a guide on the top surface of the mandrel for cutting provides a clear, easy, and safe cutting path.
  • the guide can be grooved/concave or convex.
  • the commissure edges of the mandrel can be sharp like a blade to facilitate leaflet separation and to improve on the quality of the cut edges.
  • the gap portion 910 of the mandrel can have various top profiles to facilitate sealing of the leaflets and/or separation of the leaflets prior to removal from mandrel 900 .
  • the gap portion 910 can have a grooved profile as depicted in FIG. 14A , a concave profile as depicted in FIG. 14B , or an angled profile as depicted in FIG. 14C .
  • a heating element e.g., an Ohmic or resistive heating element such as a wire
  • the stent-mounted valve 100 can be implanted with smaller diameter than its manufactured diameter for reducing leakage and improving durability.
  • FIGS. 15A, 15B, and 16 a method for fabricating a valve is depicted.
  • a bare stent 102 and a bare mandrel 900 are provided.
  • the stent 102 can be first coated with a polymer such as PEEK or other metal surface modifier prior to further dip coating of the stent 102 in another polymer in order to improve adhesion of the leaflet polymer 106 to the metal stent 102 .
  • a polymer such as PEEK or other metal surface modifier
  • the bare mandrel 900 can optionally be coated with a release agent to promote separation of the polymer leaflets from the mandrel 900 .
  • Both the bare stent 102 and the mandrel 900 are dip coated separately in a polymer, which may be the same or different for the bare stent 102 and the mandrel 900 .
  • the leaflets 106 formed on the mandrel 900 can be removed prior to introduction to the coated stent.
  • the coated mandrel 900 can be introduced into the coated stent, the leaflets 106 can be bonded to the coated stent, and the mandrel 900 can be then be removed to leave the assembled valve 100 .
  • Leaflets 106 can be bonded to the dip-coated stent using a variety of techniques including gluing, chemical fusing (i.e., dissolving the polymers) thermal fusing, sonic welding, stitching, mechanical fastening, and the like.
  • gluing i.e., dissolving the polymers
  • thermal fusing i.e., thermal fusing
  • sonic welding i.e., sonic welding
  • stitching i.e., stitching, mechanical fastening, and the like.
  • the entire valve could be formed in a single dip coating (or series of dip coatings) through use of production-grade manufacturing techniques and other optimizations.
  • stent 102 and leaflets 106 can be fabricated based on a diameter that is slightly larger than the placement location as depicted in FIG. 17A .
  • the leaflets 106 When deployed to a location having a smaller diameter than the manufactured diameter, the leaflets 106 will be held in tight contact with each other as seen in FIG. 17B to form a tight seal.
  • the deployed diameter In order to form a press fit with the vessel wall, the deployed diameter will be greater than the vessel diameter, but less than the manufactured diameter.
  • the coaptation regions of leaflets 106 have a substantially hyperbolic profile both at the manufactured diameter and the deployed diameter.
  • FIG. 17C a high-speed photograph of a closed valve under pressure during in vitro testing in a hemodynamic pulse duplicator is provided.
  • the leaflets 106 can be formed from the same or different polymer with which the stent 102 is coated to form wall 104 .
  • the leaflets 106 can be formed from polymers such as polyethylene, polyurethane, silicone, and the like.
  • Wall 104 can be formed from polyethylene, polyurethane, silicone, and the like.
  • Supplementary materials such as directional fibers can mixed into the polymer solution or applied to the leaflets between coatings in order to increase durability
  • the selected polymer can be dissolved by a solvent such as tetrahydrofuran or dimethylacetamide.
  • the thickness of the coated polymer can be controlled as a function of the density of the polymer solution and total number of dippings. When the polymer becomes dry after dipping, the coated stent and mandrel can be placed horizontally and axially rotated in order to produce a constant thickness and prevent the polymer from dripping.
  • the valve to be implanted can be a valve 100 as described herein.
  • step S 1802 the valve is placed over an expander and within a sheath.
  • Various surgical expanders and access devices exist in the cardiac surgery field.
  • a balloon catheter could be introduced into a patient's femoral artery and guided to the location of the implanted valve (e.g., within the patient's heart or systemic veins).
  • step S 1804 the sheath (containing the valve and the expander) is introduced into a vessel of the subject.
  • step S 1806 the valve and the expander are advanced from the sheath and positioned in the desired location.
  • step S 1808 the desired positioning can be verified using various imaging techniques such as fiber optics, ultrasound, X-ray, and the like.
  • step S 1810 the expander is actuated within the valve to expand the valve to form a press fit against the vessel in which the valve is implanted.
  • a balloon catheter can be expanded by introducing gas or a liquid into the balloon.
  • step S 1812 the desired positioning and expansion can be verified using various imaging techniques such as fiber optics, ultrasound, X-ray, and the like.
  • step S 1814 the expander and sheath can be retracted according to standard surgical techniques.
  • the implanted valve can be a valve 100 as described herein.
  • step S 1902 an expander is introduced into the implanted valve.
  • step S 1904 the expander is actuated within the implanted valve to increase the diameter of the implanted valve.
  • step S 1906 the desired expansion can be verified using various imaging techniques.
  • step S 1908 the expander can be retracted according to standard surgical techniques.
  • embodiments of the invention are described and depicted in the context of percutaneous, transcatheter valves having expandable, cylindrical stents
  • embodiments of the invention described herein can be applied to surgically-implanted valves that generally include anchors having fixed-diameter anchors supporting a plurality of leaflets (e.g., the CARPENTIER-EDWARDSTM series of valves available from Edwards Lifesciences Corporation of Irvine, Calif.).
  • the anchor replaces the expandable, cylindrical stents described herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Prostheses (AREA)

Abstract

One aspect of the invention provides and artificial, flexible valve indlucding: a stent defining a wall and a plurality of leaflets extending from the wall of the stent. The plurality of leaflets form a plurality of coaptation regions between two adjacent leaflets. The coaptation regions include extensions along a z-axis and adapted and are configured to form a releasable, but substantially complete seal when the leaflets are in a closed position. Another aspect of the invention provides an artificial, flexible valve including: a stent defining a wall and a plurality of leaflets extending from the wall of the stent. Each of the plurality of leaflets terminates in a commissure line. The commissure lines devi-ate from a hyperbola formed in the x-y plane by at least one deviation selected from the group consisting of: a deviation in the z-direction and one or more curves relative to the hyperbola.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This application claims priority to U.S. Provisional Patent Application Ser. No. 61/989,820, filed May 7, 2014. The entire content of this application is hereby incorporated by reference herein.
  • BACKGROUND OF THE INVENTION
  • Valves exist in the body (e.g., in the heart and the systemic veins) to allow unidirectional blood flow. A variety of congenital conditions, infectious diseases (e.g., rheumatic heart disease), endocarditis, and age-related impairments (e.g., senile stenosis) can necessitate implantation of an artificial valve.
  • SUMMARY OF THE INVENTION
  • One aspect of the invention provides an artificial, flexible valve including: a stent defining a wall and a plurality of leaflets extending from the wall of the stent. The plurality of leaflets form a plurality of coaptation regions between two adjacent leaflets. The coaptation regions include extensions along a z-axis and adapted and are configured to form a releasable, but substantially complete seal when the leaflets are in a closed position.
  • This aspect of the invention can have a variety of embodiments. The extensions can have a length along the z-axis between about 1 mm and about 10 mm. The extensions can have a curved profile. The curved profile can lie in an x-y plane. The curved profile can be a variance in extension length along the z-axis.
  • The coaptation regions can have a substantially hyperbolic profile. Each of the plurality of leaflets can have a substantially elliptical leaflet-stent attachment line. The stent can be an expandable, cylindrical stent. The leaflets can be reinforced with one or more selected from the group consisting of: reinforcing materials and directional fibers. One or more selected from the group consisting of: coaptation regions and leaflet-stent attachment lines can be reinforced with one or more selected from the group consisting of: additional polymer thickness, reinforcing materials, and directional fibers.
  • Adjacent leaflets can be coupled to a wide post of the stent. The wide post can include one or more windows. The wide post can have a width between about 0.5 mm and about 3 mm.
  • The stent can include metal or plastic. The metal can be selected from the group consisting of: stainless steel, 316L stainless steel, cobalt-chromium alloys, and nickel-titanium alloys.
  • The leaflets can be formed from a first polymer. The first polymer can be selected from the group consisting of: polytetrafluoroethylene, polyethylene, polyurethane, silicone, and copolymers thereof.
  • The stent can be dip-coated in a second polymer. The second polymer can be selected from the group consisting of: polytetrafluoroethylene, polyethylene, polyurethane, silicone, and copolymers thereof. The leaflets can be coupled to the second polymer. The leaflets can be mechanically coupled to the second polymer. The leaflets can be chemically coupled to the second polymer. The leaflets can be coupled to the second polymer by one or more techniques selected from the group consisting of: gluing, chemical fusing, thermal fusing, sonic welding, stitching, and mechanical fastening.
  • A leaflet-stent attachment line for each of the plurality of leaflets can substantially approximate a frame of the stent. The leaflet-stent attachment line can lie within about 3 mm of the frame of the stent.
  • The stent can include one or more anchor points. The anchor points can contain a radio-opaque material.
  • The valve can be adapted and configured for replacement of one or more cardiac valves selected from the group consisting of: aortic, mitral, tricuspid, and pulmonary.
  • The valve can be adapted and configured for insertion in a subject's veins in order to treat venous insufficiency. The valve can be adapted and configured for serial expansion as the subject ages.
  • Another aspect of the invention provides an artificial, flexible valve including: a stent defining a wall and a plurality of leaflets extending from the wall of the stent. Each of the plurality of leaflets terminates in a commissure line. The commissure lines deviate from a hyperbola formed in the x-y plane by at least one deviation selected from the group consisting of: a deviation in the z-direction and one or more curves relative to the hyperbola.
  • This aspect of the invention can have a variety of embodiments. The leaflets can further include extensions beyond the commissure lines along a z-axis. The extensions can have a length along the z-axis between about 1 mm and about 10 mm. The extensions can have a curved profile. The curved profile can lie in an x-y plane. The curved profile can be a variance in extension length along the z-axis.
  • Each of the plurality of leaflets can have a substantially elliptical leaflet-stent attachment line. The stent can have an expandable, cylindrical stent. The leaflets can be reinforced with one or more selected from the group consisting of: reinforcing materials and directional fibers.
  • One or more selected from the group consisting of: coaptation regions and leaflet-stent attachment lines can be reinforced with one or more selected from the group consisting of:
  • additional polymer thickness, reinforcing materials, and directional fibers.
  • Adjacent leaflets can be coupled to a wide post of the stent. The wide post can include one or more windows. The wide post can have a width between about 0.5 mm and about 3 mm.
  • The stent can include metal or plastic. The metal can be selected from the group consisting of: stainless steel, 316L stainless steel, cobalt-chromium alloys, and nickel-titanium alloys.
  • The leaflets can be formed from a first polymer. The first polymer can be selected from the group consisting of: polytetrafluoroethylene, polyethylene, polyurethane, silicone, and copolymers thereof.
  • The stent can be dip-coated in a second polymer. The second polymer can be selected from the group consisting of: polytetrafluoroethylene, polyethylene, polyurethane, silicone, and copolymers thereof. The leaflets can be coupled to the second polymer. The leaflets can be mechanically coupled to the second polymer. The leaflets can be chemically coupled to the second polymer. The leaflets can be coupled to the second polymer by one or more techniques selected from the group consisting of: gluing, chemical fusing, thermal fusing, sonic welding, stitching, and mechanical fastening.
  • A leaflet-stent attachment line for each of the plurality of leaflets can substantially approximate a frame of the stent. The leaflet-stent attachment line can lie within about 3 mm of the frame of the stent.
  • The stent can include one or more anchor points. The anchor points can contain a radio-opaque material.
  • The valve can be adapted and configured for replacement of one or more cardiac valves selected from the group consisting of: aortic, mitral, tricuspid, and pulmonary.
  • The valve can be adapted and configured for insertion in a subject's veins in order to treat venous insufficiency. The valve can be adapted and configured for serial expansion as the subject ages.
  • Another aspect of the invention provides an artificial, flexible valve including: an expandable, cylindrical stent defining a wall and a plurality of leaflets extending from the wall of the stent. Adjacent leaflets can be coupled to a relatively wide post of the stent.
  • The leaflets can further include extensions beyond the commissure lines along a z-axis. The extensions can have a length along the z-axis between about 1 mm and about 10 mm. The extensions can have a curved profile. The curved profile can lie in an x-y plane. The curved profile can be a variance in extension length along the z-axis.
  • The coaptation regions can have a substantially hyperbolic profile. Each of the plurality of leaflets can have a substantially elliptical leaflet-stent attachment line. The leaflets can be reinforced with one or more selected from the group consisting of: reinforcing materials and directional fibers.
  • One or more selected from the group consisting of: coaptation regions and leaflet-stent attachment lines can be reinforced with one or more selected from the group consisting of: additional polymer thickness, reinforcing materials, and directional fibers.
  • The relatively wide post can include one or more windows. The relatively wide post can have a width between about 0.5 mm and about 3 mm.
  • The stent can include metal or plastic. The metal can be selected from the group consisting of: stainless steel, 316L stainless steel, cobalt-chromium alloys, and nickel-titanium alloys.
  • The leaflets can be formed from a first polymer. The first polymer can be selected from the group consisting of: polytetrafluoroethylene, polyethylene, polyurethane, silicone, and copolymers thereof.
  • The stent can be dip-coated in a second polymer. The second polymer can be selected from the group consisting of: polytetrafluoroethylene, polyethylene, polyurethane, silicone, and copolymers thereof. The leaflets can be coupled to the second polymer. The leaflets can be mechanically coupled to the second polymer. The leaflets can be chemically coupled to the second polymer. The leaflets can be coupled to the second polymer by one or more techniques selected from the group consisting of: gluing, chemical fusing, thermal fusing, sonic welding, stitching, and mechanical fastening.
  • A leaflet-stent attachment line for each of the plurality of leaflets can substantially approximate a frame of the stent. The leaflet-stent attachment line can lie within about 3 mm of the frame of the stent.
  • The stent can include one or more anchor points. The anchor points can contain a radio-opaque material.
  • The valve can be adapted and configured for replacement of one or more cardiac valves selected from the group consisting of: aortic, mitral, tricuspid, and pulmonary. The valve can be adapted and configured for insertion in a subject's veins in order to treat venous insufficiency. The valve can be adapted and configured for serial expansion as the subject ages. The valve may not contain any animal-derived materials.
  • Another aspect of the invention provides a mandrel including: a cylindrical profile and a plurality of recesses adapted and configured to define a plurality of leaflets forming a plurality of coaptation regions between two adjacent leaflets. The coaptation regions can include extensions along a z-axis and be adapted and configured to form a releasable, but substantially complete seal when the leaflets are in a closed position.
  • This aspect of the invention can have a variety of embodiments. The mandrel can include one more cutting guides located between the plurality of recesses. The mandrel can include one or more heating elements.
  • Another aspect of the invention provides a mandrel including: a cylindrical profile and a plurality of recesses adapted and configured to define a plurality of leaflets. Each of the plurality of leaflets terminate in a commissure line. The commissure lines deviate from a hyperbola formed in the x-y plane by at least one deviation selected from the group consisting of: a deviation in the z-direction and one or more curves relative to the hyperbola.
  • This aspect of the invention can have a variety of embodiments. The mandrel can include one more cutting guides located between the plurality of recesses. The mandrel can include one or more heating elements.
  • Another aspect of the invention provides a method for fabricating an artificial, flexible valve. The method includes: dip coating a cylindrical mandrel having a plurality of recesses each approximating a profile of a leaflet and coupling the leaflets to an inner wall of a stent.
  • This aspect of the invention can have a variety of embodiments. The method can further include dip coating the stent prior to coupling the leaflets to the inner wall of the stent. The stent and the mandrel can have larger diameters than a target location for the valve. The method can further include separating adjacent leaflets from each other.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • For a fuller understanding of the nature and desired objects of the present invention, reference is made to the following detailed description taken in conjunction with the accompanying drawing figures wherein like reference characters denote corresponding parts throughout the several views and wherein:
  • FIGS. 1A and 1B provide perspective (in which fluid flows from the bottom of the stent toward the top of the stent) and top (in which fluid flows out of the page when the valve is open and flows down into the page to close the valve) views of a valve according to an embodiment of the invention;
  • FIG. 2 depicts a stent according to an embodiment of the invention;
  • FIGS. 3A-3F depict various stent geometries according to embodiments of the invention;
  • FIG. 4 depicts various vertical post geometries according to embodiments of the invention;
  • FIGS. 5A-5D depict the positioning of a leaflet joint adjacent to a window of a vertical post according to an embodiment of the invention;
  • FIG. 6 depicts a stent prior to expansion, dip coating, and leaflet installation according to an embodiment of the invention;
  • FIG. 7 depicts a stent including one or more anchor points according to an embodiment of the invention;
  • FIG. 8 depicts the engagement of a stent with a holder for dipping and rotation according to an embodiment of the invention;
  • FIGS. 9A-9E depict a mandrel according to an embodiment of the invention;
  • FIG. 9F depicts the positioning of a hyperbolic commissure line relative to defined asymptotes according to embodiments of the invention;
  • FIG. 10A depicts a comparison of elliptical vs. parabolic geometries leaflet valley lines according to embodiments of the invention;
  • FIGS. 10B and 10C depict a comparison of elliptical vs. parabolic leaflet stent attachment lines according to embodiments of the invention;
  • FIGS. 11A-11D depict mandrels for forming coaptation regions of varying height according to embodiments of the invention;
  • FIGS. 12A-12D depict mandrels for forming coaptation regions of varying radial length according to embodiments of the invention;
  • FIGS. 12E-12H depict mandrels for forming commissure lines having variable depths along the z-axis according to embodiments of the invention;
  • FIGS. 121-12K depict mandrels for forming coaptation regions having curved profiles in an x-y plane, resulting in increased coaptation length, according to embodiments of the invention;
  • FIGS. 12L-12N depict mandrels for forming commissure lines having curved profiles in an x-y plane, resulting in increased coaptation length, according to embodiments of the invention;
  • FIG. 13A depicts a mandrel according to an embodiment of the invention;
  • FIGS. 13B and 13C depict the positioning of reinforcing zones on a mandrel according to an embodiment of the invention;
  • FIGS. 14A-14C depict various top profiles according to an embodiment of the invention;
  • FIGS. 15A and 15B depict the fabrication of valves according to embodiments of the invention;
  • FIG. 16 depict the fabrication of valves according to an embodiment of the invention;
  • FIGS. 17A and 17B depict the compression of a valve after assembly in order to bring leaflets into contact with each other according to embodiments of the invention;
  • FIG. 17C is a high-speed photograph of a closed valve under pressure according to embodiments of the invention;
  • FIG. 18 depicts a method of implanting a valve according to embodiments of the invention; and
  • FIG. 19 depicts a method of expanding an implanted valve according to embodiments of the invention.
  • DEFINITIONS
  • The instant invention is most clearly understood with reference to the following definitions.
  • As used herein, the singular form “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise.
  • Unless specifically stated or obvious from context, as used herein, the term “about” is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. “About” can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from context, all numerical values provided herein are modified by the term about.
  • As used in the specification and claims, the terms “comprises,” “comprising,” “containing,” “having,” and the like can have the meaning ascribed to them in U.S. patent law and can mean “includes,” “including,” and the like.
  • Unless specifically stated or obvious from context, the term “or,” as used herein, is understood to be inclusive.
  • Ranges provided herein are understood to be shorthand for all of the values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 (as well as fractions thereof unless the context clearly dictates otherwise).
  • DETAILED DESCRIPTION OF THE INVENTION
  • Aspects of the invention provide a novel platform that allows development of polymeric valves of any size and shape. Aspects of the invention can be applied to valves designed for surgical implantation (e.g., through a sternotomy or thoracotomy) or valves designed for percutaneous, transcatheter implantation. Additionally, embodiments of the invention allow for possible percutaneous replacement of a dysfunctional valve, whether in adults or in small children. In addition, if implanted in a child, embodiments of the invention allow the valve to be serially expanded to accompany the child's growth.
  • Cardiac Applications
  • Multiple types of congenital heart defects require heart valve replacement surgery in infancy or childhood. In adults, the most commonly replaced valves are aortic and mitral, whereas in children, the pulmonary valve is the most commonly replaced valve. Heart valves are currently replaced using tissue valves (homograft or xenograft) or mechanical metal valves, each having their shortcomings. Homograft valves are in short supply, particularly in sizes suitable for use in children, and biologic tissue-based valves (whether bovine, porcine, or homograft) tend to induce an immunologic reaction which leads to failure of these valves. Mechanical valves generally require anticoagulation, and are almost never used in the pulmonary position due to an increased risk of thrombosis.
  • Furthermore, none of the surgically implanted valves can adapt to growing patients. The rapid growth of pediatric patients leads them to outgrow their implanted valves within a few years and induces a cycle of frequent surgical valve replacements during childhood. Aspects of the invention provide valves having improved biocompatibility, durability, and hemodynamic performance and would reduce the frequency of recurrent open heart surgeries for valve replacement.
  • Venous Applications
  • Additionally, aspects of the invention can be used for venous valve replacement in patients having venous disease such as chronic venous insufficiency (leading to leg swelling). Because the polymer leaflets can be made extremely thin, the valves can even open under extremely low venous pressure gradients.
  • Artificial, Flexible Valves
  • Referring now to FIGS. 1A and 1B, one aspect of the invention provides an artificial, flexible valve 100. The valve includes an expandable, cylindrical stent 102 defining a wall 104. Valve 100 further includes a plurality of leaflets 106 a-106 c. Wall 104 can be formed by dip coating stent 102 in a polymer as further described herein. Leaflets 106 can be coupled to wall 104 along seams 108 using a variety of approaches (e.g., glue) as discussed further herein. Stent 102 can include one or more vertical posts 110, 112, which can be relatively narrow posts 110 or relatively wide posts 112. Preferably leaflet joints between adjacent leaflets 106 are positioned on or close to a vertical post 110, 112 of the stent 102.
  • The valve 100 will now be described in the context of its components and methods of fabrication.
  • Stents
  • Referring now to FIG. 2, stent 102 can be a metallic stent having plurality of wires, strips, and the like 202 defining a plurality of cells 204, 206 of various sizes. Stent 102 can be fabricated from a variety of malleable materials such as stainless steel, 316L stainless steel, cobalt-chromium alloys, nickel-titanium alloys (colloquially known as “nitinol”), and the like. Stent 102 can also be formed from various non-metallic materials such as plastics such as polyethylene, polyurethane, polytetrafluoroethylene (PTFE), silicone, poly(propylene) (PP), polyethylene terephthalate (PET), and the like.
  • Stent 102 can be completely enveloped by a polymer dip coating. Stent 102 and/or wall 104 can also be fabricated from a biocompatible material.
  • The stent 102 can be manufactured by laser cutting or wire forming. To increase bonding strength between metal and polymer, roughness of stent surface can be controlled. Some or all open cells 204, 206 of the stent can be covered as the bare 102 stent is dipped into the polymer solution.
  • FIG. 6 depicts a stent 102 prior to expansion, dip coating, and leaflet installation. Stents 102 typically have a diameter of between about 2 mm and 6 mm prior to expansion and can be expanded to between about 5 mm and about 30 mm for implantation into a subject.
  • The components of stent 102 can have a variety of dimensions that can be selected to achieve a desired flexibility, rigidity, resilience, and the like. For example, the thickness and width of components of the stent 102 can be between about 0.1 mm and about 2 mm.
  • As discussed above, stent 102 can include one or more vertical posts 110 a-110 c to enhance bonding with leaflets 106.
  • Stent 102 can include a plurality of vertical posts 110 that can serve a variety of functions. Some vertical posts 110 can include additional structure and are referred to herein as wide posts 112. Wide posts 112 are preferably located at leaflet joints where two leaflets 106 meet. For example, in a valve 100 having a three leaflets 106, wide posts 112 can be positioned at 120° intervals within cylindrical stent 102.
  • Wide posts 112 provide mechanical support to leaflets and prevent or substantially limit inward deformation of wall 104 due to tensile forces applied to leaflets 106 transferred to wall 104. Without being bound by theory, it is believed that the wide posts 112 provide increased strength and resiliency due to formation of polymer wall 104 through windows 206 and around wide posts 112, thus providing cohesive holding of the polymer to itself around the stent 102 instead of relying solely on adhesive bonding of the polymer wall 104 to the stent 102.
  • Wide posts 112 advantageously allow for relaxed tolerances in positioning leaflets 106 relative to wide posts 112. For example, window 208 can have a width of between about 0.5 mm and about 3 min (e.g., about 1 mm) and a height of between about 1 mm and about 10 mm (e.g., about 5 mm).
  • A variety of additional wide post geometries are depicts in FIGS. 3A-3F. In FIG. 3A, the wide posts have a solid architecture without any windows. In FIG. 3B, the wide posts have a substantially rectangular architecture defining a single, long window as in FIGS. 1A, 1B, and 2. In FIG. 3C, the wide posts define a plurality of coaxial substantially rectangular windows. In FIG. 3D, the wide posts define a plurality of coaxial, substantially parallel windows. In FIG. 3E, the wide posts define a plurality of coaxial, substantially rectangular windows in a 2×3 arrangement. In FIG. 3F, the wide posts include a plurality of circular windows. These wide post architectures are further depicted in FIG. 4. Although substantially circular and rectangular window geometries are depicted, any geometry can be utilized including windows having a profile approximating a triangle, a square, an n-gon (e.g., a hexagon, an octagon, and the like), and the like.
  • Referring now to FIGS. 5A-5D, the positioning of a leaflet joint 502 (formed, e.g., on mandrel 900 as discussed herein) adjacent to window 206 of wide post 112 is depicted. (The polymer dip-coated wall 104 is completely transparent for case and clarity in viewing, but can be transparent, translucent, or opaque.) FIG. 5B-5D further depict how a geometry of the stent 102 can be selected to substantially approximate the leaflet-stent attachment seam 108 discussed herein in order to provide added mechanical support and resiliency.
  • Referring now to FIG. 7, stent 102 can include one or more anchor points 702. Anchor points 702 advantageously facilitate holding, dipping, and rotation of the stent 102 during the dip coating process without interfering with the dip coating of the remainder of the stent architecture. Accordingly, the entire stent 102 can be dip coated in a single dipping, although multiple dippings can be utilized to control coating density, thickness, and the like. Anchor points 702 can also receive one or more radio-opaque materials such as platinum to aid in placement and visualization of the valve.
  • In one embodiments depicted in FIG. 8, stent 102 can be engaged with a holder 802 (e.g., by posts 804) for dipping and rotation. Once the polymer (again depicted as, but not necessarily, transparent) is wet on the stent 102, the stent can be positioned horizontally and rotated axially.
  • Leaflets
  • Leaflets 106 can be formed using a variety of techniques including dip coating, 3D-printing (also known as additive manufacturing), molding, and the like.
  • Referring now to FIG. 9A, leaflets 106 can be fabricated by dip coating a mandrel 900 with a polymer. The mandrel 900 can be made with a solid such as a metal (e.g., stainless steel, titanium, aluminum, and the like), a plastic (e.g., polyethylene, polypropylene, polyvinyl chloride, polytetrafluoroethylene, polyoxymethylene, and the like), and the like. Since the coated polymer leaflets 106 will be removed from the mandrel 900 after the polymer dries, roughness of mandrel surface can be controlled using known machining and other manufacturing techniques. The mandrel 900 can be made from a cylinder. Preferably, the diameter of the mandrel 900 is a slightly (e.g., between about 0.05 and about 0.4 mm) smaller than inner diameter of stent 102 after expansion.
  • The mandrel 900 for the leaflets 106 can have novel features, including edges representing the leaflet attachment points that are mathematically defined and leaflet tips that are extended in order to increase the coaptation length of the leaflets. The mandrel 900 can be dimensioned to produce leaflets 106 having different regional thickness and supplementary materials such as directional fibers or reinforcing particles inserted between layers or mixed into the polymer solution in order to increase durability. For example, polymer interaction with particles on the nanoscale or microscale can greatly improve the physical properties or tear resistance of the polymer leaflets 106.
  • Mandrel 900 can be designed to have a complementary geometry to the desired leaflet shape and permits easier viewing of leaflet geometry. Although mandrel 900 is utilized to describe the geometry of the leaflet 106, it should be recognized that the upstream surface of the resulting leaflets will have this geometry when formed by dip coating and that the complementary geometry of the leaflet(s) 106 can be produced using techniques other than dip coating. Mandrel 900 is preferably cylindrical and can have an outer profile substantially approximating an inner profile of stent 102. Mandrel 900 can define a plurality of pockets 902 that each define a leaflet 106 as it hangs from wall 104 via attachment line 108. Each leaflet 106 terminates in a commissure line 904 often, but not necessarily lying in a plane at the point where the elliptical or parabolic curve ends and where the leaflet often contacts the other leaflets. A substantially vertical coaptation region 906 can extend beyond the commissure line 904 to an extended commissure line 912 for improved sealing as will be discussed herein.
  • Referring now to FIGS. 9B and 9C, mandrel can be cast, machined, printed, or otherwise fabricated so that pockets 902 have a desired geometry. In one embodiment of the invention, the commissure line 904 (and optionally the coaptation region 906 and extended commissure line 912) has a substantially hyperbolic profile when viewed in the x-y plane. Additionally or alternatively, leaflet-stent attachment line 108 and/or a leaflet valley line 908 (formed by taking a cross-section in a z plane) can have substantially elliptical profiles. Although other quadratic profiles (e.g., parabolic) could be used, elliptical profiles better promote a secure pocket shape and the closure of the leaflet-stent attachment line 108 to the contour of the cylindrical mandrel 900. A comparison of elliptical vs. parabolic leaflet valley lines is provided in FIG. 10A. A comparison of elliptical vs. parabolic leaflet-stent attachment lines is provided in FIGS. 10B and 10C.
  • Referring now to FIG. 9D, mandrel 900 can define a gap 910 between adjacent leaflets. Advantageously, leaflets 106 with a hyperbolic profile can produce smaller gaps than leaflets with parabolic profiles. For example, gaps 910 can be less than 1 mm or between about 0.1 mm and about 1 mm (e.g., between about 0.1 mm and about 0.2 mm, between about 0.2 mm and about 0.3 mm, between about 0.3 mm and about 0.4 mm, between about 0.4 mm and about 0.5 mm, between about 0.5 mm and about 0.6 mm, between about 0.6 mm and about 0.7 mm, between about 0.7 mm and about 0.8 mm, about 0.8 mm and about 0.9 mm, about 0.9 mm and about 1 mm, and the like).
  • As seen in FIG. 9E, the length of hyperbolic commissure line 904 is about twice the radius of the stent or mandrel. The positioning of a hyperbolic commissure line 904 relative to defined asymptotes is depicted in FIG. 9F.
  • Referring now to FIG. 11A, coaptation region can have minimal height in the z-axis so as to consist only of the commissure line 904. Alternatively, coaptation region 906 can have a vertical extension in the z-axis to an extended commissure line 912 as depicted in FIGS. 11B-11D. The height of the coaptation region 906 can be selected to reduce the amount of regurgitation, while still allowing the valve to open. For example the coaptation region 906 can have a height between about 1 mm and about 10 mm (e.g., about 3 mm). Although FIGS. 11B-11D depict extensions of coaptation region 904 that extend solely in the z-axis, the same effect can be achieved using a smooth leaflet-stent attachment line that extends in the z-axis so that the adjacent leaflet-stent attachment lines (and/or the regions of lealets hanging therebetween) approach and/or contact each other to form an extended coaptation region.
  • The zone of coaptation is affected by the pressure placed upon the closed valve 100. The higher the pressure, the more downward tension is placed on the leaflets 106, possibly leading to a failure of coaptation with consequent regurgitation. Proper coaptation also allows the leaflets 106 to support each other, so there is less stress placed on any individual leaflet 106. Another benefit of enhancing height of the coaptation zone is that this allows the valve 100 to be re-dilated to a larger diameter late after implantation (such as to accommodate growth of a pediatric patient), while still maintaining competence of the valve 100.
  • Options for enhancing the height of the coaptation zone include creating excess length of the leaflet free edges, so that the free edge length is greater than twice the radius of the stent or mandrel depicted in FIG. 9E. Lengthening of the leaflet free edges can be accomplished by curved edges in the x-y plane, or in the z-axis, or in all 3 axes.
  • Referring now to FIGS. 12A-12D, coaptation regions 906 can have varying heights in the z-axis between the commissure line 904 and extended commissure line 912. For example, the height of coaptation region 906 can increase toward the outside of the mandrel as depicted in FIG. 12B. In another embodiment, the height of the coaptation region 906 can dip to form a trough between the outside and the center of the mandrel 900 as depicted in FIG. 12C.
  • Referring now to FIGS. 12E-12H, the same profiles can be applied to commissure line 904 without any coaptation region 906.
  • Referring now to FIGS. 121-12K, the commissure lines 904, coaptation regions 906 and/or extended commissure lines 912 can have curved profiles in an x-y plane (as opposed to a substantially hyperbolic profile) in order to increase the length of the commissure line 904, coaptation region 906, and/or extended commissure line 912. For example, the mandrel 900 can be thicker between the perimeter and the center as depicted in FIG. 121 to produce one or more scallops. In FIGS. 12J and 12K, the mandrel 900 can have either a single curve or multiple curves.
  • Referring now to FIGS. 12L-12N, the same profiles can be applied to commissure line 904 without any coaptation region 906.
  • In order to increase tear-resistance of the leaflets 106 and enhance bonding strength between leaflets 106 and stent 102, the thickness of the leaflets 106 can be controlled regionally. Because the most common failure points are at the outer edges of the leaflets 106 (such as commissure line 904 or extended commissure line 912 and leaflet-stent attachment line 108), increased thickness at outer areas of the leaflets 106 can improve the strength and durability. Also, if local areas are expected to have concentrated stress, the areas can be locally reinforced (e.g., made thicker than other areas). The thickness can be smoothly increased. The width of thickened area along leaflet-stent attachment line 108 can be large enough to cover the glued area for bonding the leaflets 106 and the covered stent 102. In some embodiments, the thickness of thickened areas of the leaflets is between about 0.1 mm and about 1 mm.
  • Multiple dippings can be performed to produce leaflets with a desired thickness. In some embodiments, the thickness of the leaflets is between about 0.01 mm and about 0.2 mm.
  • Different reinforcing materials such as strips, fibers and particles can be placed between the layers, or directly mixed into the polymer solution. The inserted material(s) can prevent tearing and reduce propagation of the tear if it occurs. The materials can have directional properties and can be layered onto, or embedded into, the leaflets in an optimal direction to prevent or limit tears.
  • Referring now to FIG. 13A, a photograph of a mandrel 900 is provided. Referring now to FIG. 13B, a reinforcing zone 1302 can be formed on the mandrel 900 prior either by removing mandrel material to allow for additional thickness in certain (e.g., outer) regions of leaflets 106 or by introducing one or more reinforcing fibers prior to, during, or after dip coating. Suitable reinforcing materials include fibers (e.g., polymers, nanotubules, aramids, para-aramids, and the like), wires, and the like. Transitions between reinforced and non-reinforced areas can be smooth in order to minimize any turbulence in the implanted valve 100.
  • After dipping the mandrel 900 into the polymer solution, the coated polymer dries in order to form the leaflet(s) 106. Because the formed leaflets 106 are connected, they need to be separated from each other. These can be cut by a sharp cutter (e.g., a knife, a scalpel, a razor blade, a utility knife, and the like), a heated iron, a laser, a rotary tool, and the like. A guide on the top surface of the mandrel for cutting provides a clear, easy, and safe cutting path. The guide can be grooved/concave or convex. Also, the commissure edges of the mandrel can be sharp like a blade to facilitate leaflet separation and to improve on the quality of the cut edges.
  • Referring now to FIG. 14A-14C, the gap portion 910 of the mandrel can have various top profiles to facilitate sealing of the leaflets and/or separation of the leaflets prior to removal from mandrel 900. For example, the gap portion 910 can have a grooved profile as depicted in FIG. 14A, a concave profile as depicted in FIG. 14B, or an angled profile as depicted in FIG. 14C. Additionally or alternatively, a heating element (e.g., an Ohmic or resistive heating element such as a wire) can be included in the mandrel and can be actuated to melt the polymer to separate the leaflets and/or relax the polymer to facilitate removal of the leaflets from the mandrel 900.
  • The stent-mounted valve 100 can be implanted with smaller diameter than its manufactured diameter for reducing leakage and improving durability.
  • Methods of Fabricating Valves
  • Referring now to FIGS. 15A, 15B, and 16, a method for fabricating a valve is depicted. A bare stent 102 and a bare mandrel 900 are provided.
  • In some embodiments, the stent 102 can be first coated with a polymer such as PEEK or other metal surface modifier prior to further dip coating of the stent 102 in another polymer in order to improve adhesion of the leaflet polymer 106 to the metal stent 102.
  • The bare mandrel 900 can optionally be coated with a release agent to promote separation of the polymer leaflets from the mandrel 900.
  • Both the bare stent 102 and the mandrel 900 are dip coated separately in a polymer, which may be the same or different for the bare stent 102 and the mandrel 900.
  • The leaflets 106 formed on the mandrel 900 can be removed prior to introduction to the coated stent. Alternatively, the coated mandrel 900 can be introduced into the coated stent, the leaflets 106 can be bonded to the coated stent, and the mandrel 900 can be then be removed to leave the assembled valve 100.
  • Leaflets 106 can be bonded to the dip-coated stent using a variety of techniques including gluing, chemical fusing (i.e., dissolving the polymers) thermal fusing, sonic welding, stitching, mechanical fastening, and the like. For example, the same polymer solution used to coat either bare stent 102 and/or mandrel 900 can be applied to bond the leaflets 106 to the dip-coated stent.
  • Although separate fabrication of the polymer-coated stent and the leaflets 106 are currently preferred as a means of avoiding or minimizing air bubbles, the entire valve could be formed in a single dip coating (or series of dip coatings) through use of production-grade manufacturing techniques and other optimizations.
  • Although dipcoating was successfully used to fabricate prototypes of the valves described herein, any other manufacturing technique capable of producing flexible leaflets can be utilized. Exemplary techniques include injection molding and additive manufacturing or 3D printing. Referring now to FIGS. 17A and 17B, stent 102 and leaflets 106 can be fabricated based on a diameter that is slightly larger than the placement location as depicted in FIG. 17A. When deployed to a location having a smaller diameter than the manufactured diameter, the leaflets 106 will be held in tight contact with each other as seen in FIG. 17B to form a tight seal. (In order to form a press fit with the vessel wall, the deployed diameter will be greater than the vessel diameter, but less than the manufactured diameter.)
  • As can be seen in FIGS. 17A and 17B, the coaptation regions of leaflets 106 have a substantially hyperbolic profile both at the manufactured diameter and the deployed diameter.
  • Referring now to FIG. 17C, a high-speed photograph of a closed valve under pressure during in vitro testing in a hemodynamic pulse duplicator is provided.
  • Polymers
  • The leaflets 106 can be formed from the same or different polymer with which the stent 102 is coated to form wall 104. For example, the leaflets 106 can be formed from polymers such as polyethylene, polyurethane, silicone, and the like. Wall 104 can be formed from polyethylene, polyurethane, silicone, and the like.
  • Supplementary materials such as directional fibers can mixed into the polymer solution or applied to the leaflets between coatings in order to increase durability
  • The selected polymer can be dissolved by a solvent such as tetrahydrofuran or dimethylacetamide. The thickness of the coated polymer can be controlled as a function of the density of the polymer solution and total number of dippings. When the polymer becomes dry after dipping, the coated stent and mandrel can be placed horizontally and axially rotated in order to produce a constant thickness and prevent the polymer from dripping.
  • Implantation of Valves
  • Referring now to FIG. 18, a method 1800 of implanting an artificial valve is provided. The valve to be implanted can be a valve 100 as described herein.
  • In step S1802, the valve is placed over an expander and within a sheath. Various surgical expanders and access devices exist in the cardiac surgery field. For example, a balloon catheter could be introduced into a patient's femoral artery and guided to the location of the implanted valve (e.g., within the patient's heart or systemic veins).
  • In step S1804, the sheath (containing the valve and the expander) is introduced into a vessel of the subject.
  • In step S1806, the valve and the expander are advanced from the sheath and positioned in the desired location.
  • In step S1808, the desired positioning can be verified using various imaging techniques such as fiber optics, ultrasound, X-ray, and the like.
  • In step S1810, the expander is actuated within the valve to expand the valve to form a press fit against the vessel in which the valve is implanted. For example, a balloon catheter can be expanded by introducing gas or a liquid into the balloon.
  • In step S1812, the desired positioning and expansion can be verified using various imaging techniques such as fiber optics, ultrasound, X-ray, and the like.
  • In step S1814, the expander and sheath can be retracted according to standard surgical techniques.
  • Expansion of Implanted Valves
  • Referring now to FIG. 19, a method 1900 of expanding an implanted valve is provided. The implanted valve can be a valve 100 as described herein.
  • In step S1902, an expander is introduced into the implanted valve.
  • In step S1904, the expander is actuated within the implanted valve to increase the diameter of the implanted valve.
  • In step S1906, the desired expansion can be verified using various imaging techniques. In step S1908, the expander can be retracted according to standard surgical techniques.
  • Surgically-Implanted Valves
  • Although embodiments of the invention are described and depicted in the context of percutaneous, transcatheter valves having expandable, cylindrical stents, embodiments of the invention described herein can be applied to surgically-implanted valves that generally include anchors having fixed-diameter anchors supporting a plurality of leaflets (e.g., the CARPENTIER-EDWARDS™ series of valves available from Edwards Lifesciences Corporation of Irvine, Calif.). In such embodiments, the anchor replaces the expandable, cylindrical stents described herein.
  • EQUIVALENTS
  • Although preferred embodiments of the invention have been described using specific terms, such description is for illustrative purposes only, and it is to be understood that changes and variations may be made without departing from the spirit or scope of the following claims.
  • INCORPORATION BY REFERENCE
  • The entire contents of all patents, published patent applications, and other references cited herein are hereby expressly incorporated herein in their entireties by reference.

Claims (31)

1-100. (canceled)
101. An artificial valve, comprising:
an expandable frame configured to be implanted within a patient, the expandable frame having a maximum radial extent when the expandable frame is in a fully-expanded configuration in which the valve is in a maximum working condition; and
a plurality of leaflets disposed within and coupled to the frame, each leaflet from the plurality of leaflets extending from the frame and terminating at a free edge, each free edge having a length that is greater than the maximum radial extent of the expandable frame when the expandable frame is in its fully-expanded configuration.
102. The artificial valve of claim 101, wherein a first leaflet from the plurality of leaflets is coupled to a first portion of the frame and a second portion of the frame, a distance along the free edge of the first leaflet between the first portion of the frame and the second portion of the frame being greater than an are distance along the frame between the first portion and the second portion.
103. The artificial valve of claim 101, wherein the expandable frame has a first end, a second end, and a longitudinal z-axis defined therebetween,
the plurality of leaflets forming a coaptation region having a maximum radial extent in which the leaflets (1) coapt sufficiently to prevent fluid flow along the longitudinal z-axis in a first direction and through the coaptation region, and (2) allow fluid flow along the longitudinal z-axis in a second direction opposite the first direction,
the coaptation region having a radial extent less than the maximum radial extent when the frame is in a partially-expanded configuration such that the plurality of leaflets coapt sufficiently to prevent fluid flow along the longitudinal z-axis in the first direction and through the coaptation region, and (2) allow fluid flow along the longitudinal z-axis in the second direction.
104. The artificial valve of claim 101, wherein each free edge forms a portion of the coaptation region and the leaflet free edges collectively provide a tortuous path for fluid flow to prevent fluid flow in the predefined direction.
105. The artificial valve of claim 101, wherein each leaflet has a variable thickness in which its thickness is reduced from its attachment to the expandable frame towards its free edge.
106. The artificial valve of claim 101, wherein the free edge of each leaflet varies along a longitudinal z-axis of the expandable frame when the expandable frame is in the fully-expanded configuration.
107. The artificial valve of claim 106, wherein the longitudinal z-axis of the expandable frame is defined between a first end of the expandable frame and a second end of the expandable frame, the plurality of leaflets being configured to allow fluid flow from the first end to the second end and restrict fluid flow from the second end to the first end.
108. The artificial valve of claim 101, wherein the plurality of leaflets are formed of polymer.
109. The artificial valve of claim 101, wherein each leaflet from the plurality of leaflets is coupled to the frame along a leaflet attachment line, the leaflet attachment line including a conic portion and a linear portion extending from a point at which the conic portion terminates to the free edge of the leaflet.
110. The artificial valve of claim 101, wherein the maximum working condition is a condition in which the expandable frame is expanded to its largest possible diameter that allows sufficient coaptation between the plurality of leaflets.
111. An artificial valve, comprising:
an expandable frame configured to be implanted within a patient, the expandable frame having a maximum radial extent when the expandable frame is in a fully-expanded configuration in which the valve is in a maximum working condition; and
a plurality of leaflets disposed within and coupled to the frame, each leaflet from the plurality of leaflets extending from the frame and terminating at a free edge, each free edge varies along a longitudinal z-axis of the expandable frame when the expandable frame is in its fully-expanded configuration.
112. The artificial valve of claim 111, wherein the longitudinal z-axis of the expandable frame is defined between a first end of the expandable frame and a second end of the expandable frame, the plurality of leaflets being configured to allow fluid flow from the first end to the second end and restrict fluid flow from the second end to the first end.
113. The artificial valve of claim 111, wherein a first leaflet from the plurality of leaflets is coupled to a first portion of the frame and a second portion of the frame, a distance along the free edge of the first leaflet between the first portion of the frame and the second portion of the frame being greater than an are distance along the frame between the first portion and the second portion.
114. A mandrel, comprising:
a cylindrical profile having a plurality of recesses configured to define a plurality of valve leaflets,
the plurality of recesses each (1) extending from a valve attachment line and (2) terminating at a commissure line, each commissure line having a length greater than a diameter of the cylindrical profile.
115. The mandrel of claim 114, wherein:
each commissure line varies along a longitudinal z-axis of the cylindrical profile.
116. The mandrel of claim 114, wherein each commissure line is a first commissure line,
each valve attachment line being curved until reaching a second commissure line that is defined between the attachment line and the first commissure line, a coaptation region being defined by and linearly extending between the first commissure line and the second commissure line.
117. The mandrel of claim 114, wherein each valve attachment line includes a conic portion and a linear portion that extends from a point at which the conic portion terminates to the commissure line.
118. The mandrel of claim 114, wherein the commissure line extends from the linear portion towards a center of the cylindrical profile, the commissure line varying in height.
119. The mandrel of claim 114, wherein the commissure line extends from the linear portion towards a center of the cylindrical profile, the commissure line varying along a longitudinal z-axis of the cylindrical profile.
120. A frame for an artificial valve, comprising:
an expandable cylindrical body having a first end, a second end, and a longitudinal z-axis extending therebetween; and
a plurality of valve leaflets,
the expandable cylindrical body being formed by a plurality of posts extending substantially parallel to and circumferentially about the longitudinal z-axis, the plurality of posts including a first set of posts having a first width and a second set of posts having a second width that is greater than the first width,
the first set of posts defining a plurality of open cells therebetween that are variable in shape during expansion of the expandable cylindrical body,
each post from the second set of posts being disposed at a junction between and coupled to two valve leaflets from the plurality of valve leaflets.
121. The frame of claim 120, wherein each post from the second set of posts defines one or more windows configured to have a fixed shape during expansion of the expandable cylindrical body.
122. The frame of claim 121, wherein the second set of posts includes polymer within its one or more windows, each post from the second set of posts being coupled to the two valve leaflets via the polymer.
123. The frame of claim 120, wherein the plurality of open cells are covered.
124. The frame of claim 120, wherein the plurality of open cells are coated with a polymer.
125. The frame of claim 120, wherein the plurality of windows have a width of about 0.5 mm to about 3 mm, and a height of about 1 mm to about 10 mm.
126. The frame of claim 121, wherein the one or more windows are substantially rectangular.
127. The frame of claim 120, wherein the second set of posts consists of three posts each of which are circumferentially positioned at 120 degree intervals among the expandable cylindrical body, the plurality of valve leaflets consisting of three valve leaflets.
128. The frame of claim 120, wherein the plurality of valve leaflets are coupled to the second set of posts via at least one of a chemical coupling technique, chemical fusing, thermal fusing, or sonic welding.
129. The frame of claim 128, wherein the plurality of valve leaflets are formed of a polymer.
130. The frame of claim 120, wherein the entire external surface of the expandable cylindrical body is coated with a polymer.
US16/563,229 2014-05-07 2019-09-06 Artificial, flexible valves and methods of fabricating and serially expanding the same Abandoned US20200000581A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US16/563,229 US20200000581A1 (en) 2014-05-07 2019-09-06 Artificial, flexible valves and methods of fabricating and serially expanding the same
US17/473,653 US11464632B2 (en) 2014-05-07 2021-09-13 Transcatheter and serially-expandable artificial heart valve
US17/478,665 US11571300B2 (en) 2014-05-07 2021-09-17 Serially expanding an artificial heart valve within a pediatric patient
US17/982,232 US20230135271A1 (en) 2014-05-07 2022-11-07 Serially expanding an artificial heart valve within a pediatric patient

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461989820P 2014-05-07 2014-05-07
PCT/US2015/029442 WO2015171743A2 (en) 2014-05-07 2015-05-06 Artificial, flexible valves and methods of fabricating and serially expanding the same
US201615308667A 2016-11-03 2016-11-03
US16/563,229 US20200000581A1 (en) 2014-05-07 2019-09-06 Artificial, flexible valves and methods of fabricating and serially expanding the same

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2015/029442 Continuation WO2015171743A2 (en) 2014-05-07 2015-05-06 Artificial, flexible valves and methods of fabricating and serially expanding the same
US15/308,667 Continuation US20170189175A1 (en) 2014-05-07 2015-05-06 Artificial, flexible valves and methods of fabricating and serially expanding the same

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US17/473,653 Continuation US11464632B2 (en) 2014-05-07 2021-09-13 Transcatheter and serially-expandable artificial heart valve
US17/478,665 Continuation US11571300B2 (en) 2014-05-07 2021-09-17 Serially expanding an artificial heart valve within a pediatric patient

Publications (1)

Publication Number Publication Date
US20200000581A1 true US20200000581A1 (en) 2020-01-02

Family

ID=54393140

Family Applications (5)

Application Number Title Priority Date Filing Date
US15/308,667 Abandoned US20170189175A1 (en) 2014-05-07 2015-05-06 Artificial, flexible valves and methods of fabricating and serially expanding the same
US16/563,229 Abandoned US20200000581A1 (en) 2014-05-07 2019-09-06 Artificial, flexible valves and methods of fabricating and serially expanding the same
US17/473,653 Active US11464632B2 (en) 2014-05-07 2021-09-13 Transcatheter and serially-expandable artificial heart valve
US17/478,665 Active 2035-07-06 US11571300B2 (en) 2014-05-07 2021-09-17 Serially expanding an artificial heart valve within a pediatric patient
US17/982,232 Pending US20230135271A1 (en) 2014-05-07 2022-11-07 Serially expanding an artificial heart valve within a pediatric patient

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/308,667 Abandoned US20170189175A1 (en) 2014-05-07 2015-05-06 Artificial, flexible valves and methods of fabricating and serially expanding the same

Family Applications After (3)

Application Number Title Priority Date Filing Date
US17/473,653 Active US11464632B2 (en) 2014-05-07 2021-09-13 Transcatheter and serially-expandable artificial heart valve
US17/478,665 Active 2035-07-06 US11571300B2 (en) 2014-05-07 2021-09-17 Serially expanding an artificial heart valve within a pediatric patient
US17/982,232 Pending US20230135271A1 (en) 2014-05-07 2022-11-07 Serially expanding an artificial heart valve within a pediatric patient

Country Status (4)

Country Link
US (5) US20170189175A1 (en)
EP (1) EP3139865B1 (en)
CA (1) CA2948179C (en)
WO (1) WO2015171743A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11464632B2 (en) 2014-05-07 2022-10-11 Baylor College Of Medicine Transcatheter and serially-expandable artificial heart valve

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103491900B (en) 2010-12-23 2017-03-01 托尔福公司 System for mitral valve repair and replacement
EP4623867A3 (en) 2011-06-21 2025-11-05 Twelve, Inc. Prosthetic heart valve devices
US9763780B2 (en) 2011-10-19 2017-09-19 Twelve, Inc. Devices, systems and methods for heart valve replacement
US11202704B2 (en) 2011-10-19 2021-12-21 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US9655722B2 (en) 2011-10-19 2017-05-23 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
CA2848334C (en) 2011-10-19 2020-10-20 Twelve, Inc. Devices, systems and methods for heart valve replacement
US9039757B2 (en) 2011-10-19 2015-05-26 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
WO2013059747A1 (en) 2011-10-19 2013-04-25 Foundry Newco Xii, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US9579198B2 (en) 2012-03-01 2017-02-28 Twelve, Inc. Hydraulic delivery systems for prosthetic heart valve devices and associated methods
US9283072B2 (en) 2012-07-25 2016-03-15 W. L. Gore & Associates, Inc. Everting transcatheter valve and methods
US10376360B2 (en) 2012-07-27 2019-08-13 W. L. Gore & Associates, Inc. Multi-frame prosthetic valve apparatus and methods
US10966820B2 (en) 2012-12-19 2021-04-06 W. L. Gore & Associates, Inc. Geometric control of bending character in prosthetic heart valve leaflets
US9101469B2 (en) 2012-12-19 2015-08-11 W. L. Gore & Associates, Inc. Prosthetic heart valve with leaflet shelving
US9737398B2 (en) 2012-12-19 2017-08-22 W. L. Gore & Associates, Inc. Prosthetic valves, frames and leaflets and methods thereof
US9144492B2 (en) 2012-12-19 2015-09-29 W. L. Gore & Associates, Inc. Truncated leaflet for prosthetic heart valves, preformed valve
US9968443B2 (en) 2012-12-19 2018-05-15 W. L. Gore & Associates, Inc. Vertical coaptation zone in a planar portion of prosthetic heart valve leaflet
US10321986B2 (en) 2012-12-19 2019-06-18 W. L. Gore & Associates, Inc. Multi-frame prosthetic heart valve
US10039638B2 (en) 2012-12-19 2018-08-07 W. L. Gore & Associates, Inc. Geometric prosthetic heart valves
CN105246431B (en) 2013-05-20 2018-04-06 托尔福公司 Implantable heart valve devices, mitral valve repair devices, and related systems and methods
CA2947049C (en) 2014-05-06 2023-07-04 Dsm Ip Assets B.V. Prosthetic valve and method of making a prosthetic valve
US10314697B2 (en) 2014-08-18 2019-06-11 W. L. Gore & Associates, Inc. Frame with integral sewing cuff for prosthetic valves
US9827094B2 (en) 2014-09-15 2017-11-28 W. L. Gore & Associates, Inc. Prosthetic heart valve with retention elements
US10507101B2 (en) 2014-10-13 2019-12-17 W. L. Gore & Associates, Inc. Valved conduit
EP3337428B1 (en) 2015-08-21 2024-09-25 Twelve Inc. Mitral valve repair devices
US10265172B2 (en) 2016-04-29 2019-04-23 Medtronic Vascular, Inc. Prosthetic heart valve devices with tethered anchors and associated systems and methods
GB201616777D0 (en) 2016-10-03 2016-11-16 Univ Southampton A frame for an implantable medical device and a method of manufacturing a frame for an implantable medical device
EP3402441A4 (en) 2016-12-15 2019-09-11 Meril Life Sciences Pvt Ltd PROSTHETIC VALVE
CN108261255B (en) * 2016-12-30 2020-12-25 先健科技(深圳)有限公司 Artificial heart valve device and valve leaf and support main body thereof
US11351058B2 (en) 2017-03-17 2022-06-07 W. L. Gore & Associates, Inc. Glaucoma treatment systems and methods
US10702378B2 (en) 2017-04-18 2020-07-07 Twelve, Inc. Prosthetic heart valve device and associated systems and methods
US10433961B2 (en) 2017-04-18 2019-10-08 Twelve, Inc. Delivery systems with tethers for prosthetic heart valve devices and associated methods
US10575950B2 (en) 2017-04-18 2020-03-03 Twelve, Inc. Hydraulic systems for delivering prosthetic heart valve devices and associated methods
US10792151B2 (en) 2017-05-11 2020-10-06 Twelve, Inc. Delivery systems for delivering prosthetic heart valve devices and associated methods
US10646338B2 (en) 2017-06-02 2020-05-12 Twelve, Inc. Delivery systems with telescoping capsules for deploying prosthetic heart valve devices and associated methods
US10709591B2 (en) 2017-06-06 2020-07-14 Twelve, Inc. Crimping device and method for loading stents and prosthetic heart valves
US10729541B2 (en) 2017-07-06 2020-08-04 Twelve, Inc. Prosthetic heart valve devices and associated systems and methods
US10786352B2 (en) 2017-07-06 2020-09-29 Twelve, Inc. Prosthetic heart valve devices and associated systems and methods
CA3182971A1 (en) 2017-09-12 2019-03-21 W.L. Gore & Associates, Inc. Leaflet frame attachment for prosthetic valves
CN111132636B (en) 2017-09-27 2022-04-08 W.L.戈尔及同仁股份有限公司 Prosthetic valves with expandable frames and associated systems and methods
US11109963B2 (en) 2017-09-27 2021-09-07 W. L. Gore & Associates, Inc. Prosthetic valves with mechanically coupled leaflets
CN116725739A (en) 2017-10-13 2023-09-12 爱德华兹生命科学公司 Nested prosthetic valves and delivery systems
EP4374832A3 (en) 2017-10-31 2024-08-14 W. L. Gore & Associates, Inc. Transcatheter deployment systems and associated methods
CA3078606C (en) 2017-10-31 2023-09-05 W.L. Gore & Associates, Inc. Medical valve and leaflet promoting tissue ingrowth
WO2019089137A1 (en) 2017-10-31 2019-05-09 W. L. Gore & Associates, Inc. Valved conduit
CA3078608C (en) 2017-10-31 2023-03-28 W.L. Gore & Associates, Inc. Prosthetic heart valve
US11154397B2 (en) 2017-10-31 2021-10-26 W. L. Gore & Associates, Inc. Jacket for surgical heart valve
US10966826B2 (en) * 2017-11-16 2021-04-06 Children's Medical Center Corporation Geometrically-accommodating heart valve replacement device
WO2019118371A1 (en) * 2017-12-11 2019-06-20 California Institute Of Technology Systems, devices, and methods relating to the manufacture of intravascularly implantable prosthetic valves
US11478352B2 (en) * 2018-04-09 2022-10-25 Hangzhou Nuoyi Medtech Co., Ltd Venous valve replacement device
AU2019333136B2 (en) 2018-08-29 2022-11-17 W. L. Gore & Associates, Inc. Drug therapy delivery systems and methods
USD977642S1 (en) 2018-10-29 2023-02-07 W. L. Gore & Associates, Inc. Pulmonary valve conduit
USD926322S1 (en) 2018-11-07 2021-07-27 W. L. Gore & Associates, Inc. Heart valve cover
US11678983B2 (en) 2018-12-12 2023-06-20 W. L. Gore & Associates, Inc. Implantable component with socket
US11547557B2 (en) 2018-12-13 2023-01-10 Abbott Laboratories Stabilized fabric material for medical devices
AU2019395259A1 (en) * 2018-12-13 2021-06-10 Abbott Laboratories Fabric material for medical devices
US10702407B1 (en) * 2019-02-28 2020-07-07 Renata Medical, Inc. Growth stent for congenital narrowings
US11497601B2 (en) 2019-03-01 2022-11-15 W. L. Gore & Associates, Inc. Telescoping prosthetic valve with retention element
WO2020191386A1 (en) * 2019-03-21 2020-09-24 The Trustees Of Columbia University In The City Of New York Transcatheter dilatable biostable polymeric stented valved tube prosthesis
WO2020210794A1 (en) 2019-04-12 2020-10-15 W. L. Gore & Associates, Inc. Valve with multi-part frame and associated resilient bridging features
US20240415642A1 (en) * 2020-04-24 2024-12-19 ReValve Solutions Inc. Devices, systems, and methods for a valve replacement
IL301478A (en) * 2020-09-23 2023-05-01 Revalve Solutions Inc Devices, systems and methods for an implantable heart valve adapter
CA3197504A1 (en) * 2020-10-06 2022-04-14 Edwards Lifesciences Corporation Protective covers for prosthetic valves
BR112023025577A2 (en) * 2021-06-07 2024-02-20 Edwards Lifesciences Corp LEAFLETS AND LEAFLET SEPARATORS FOR PROSTHETIC VALVES
BR102021020737A2 (en) * 2021-10-15 2022-04-05 Angel Maluf Miguel Polyurethane-covered expandable valve stent prosthesis with the formation of anatomical cusps for catheter implantation in pulmonary position in pediatric and adult patients and method of obtaining the expandable valve stent prosthesis
WO2023095033A1 (en) * 2021-11-23 2023-06-01 Medtronic, Inc. Leaflet design for a heart valve prosthesis
JP2025525212A (en) 2022-08-03 2025-08-01 ザ チルドレンズ メディカル センター コーポレーション Geometrically adaptive heart valve replacement device
EP4378423A1 (en) * 2022-10-04 2024-06-05 Medtronic Vascular Inc. Valve prosthesis with durable prosthetic valve
WO2024124034A1 (en) * 2022-12-09 2024-06-13 Renata Medical, Inc. Transcatheter growth devices and methods for norwood, glenn and fontan therapy
CN116549736B (en) * 2023-05-29 2025-11-21 哈尔滨工业大学 Preparation method of biomedical fabric composite material film

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655306A (en) 1970-01-19 1972-04-11 Donald Nixon Ross Apparatus for molding heart valves
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US3744060A (en) 1971-06-10 1973-07-10 F Bellhouse Prosthetic cardiac valve
US4056854A (en) 1976-09-28 1977-11-08 The United States Of America As Represented By The Department Of Health, Education And Welfare Aortic heart valve catheter
NL8500538A (en) 1985-02-26 1986-09-16 Stichting Tech Wetenschapp HEART VALVE PROSTHESIS, METHOD FOR MANUFACTURING A HEART VALVE PROSTHESIS AND MOLD USED THEREIN
DE3541478A1 (en) 1985-11-23 1987-05-27 Beiersdorf Ag HEART VALVE PROSTHESIS AND METHOD FOR THE PRODUCTION THEREOF
US5411552A (en) 1990-05-18 1995-05-02 Andersen; Henning R. Valve prothesis for implantation in the body and a catheter for implanting such valve prothesis
DK124690D0 (en) 1990-05-18 1990-05-18 Henning Rud Andersen FAT PROTECTION FOR IMPLEMENTATION IN THE BODY FOR REPLACEMENT OF NATURAL FLEET AND CATS FOR USE IN IMPLEMENTING A SUCH FAT PROTECTION
US5163955A (en) * 1991-01-24 1992-11-17 Autogenics Rapid assembly, concentric mating stent, tissue heart valve with enhanced clamping and tissue alignment
AU670934B2 (en) 1992-01-27 1996-08-08 Medtronic, Inc. Annuloplasty and suture rings
GB9206449D0 (en) 1992-03-25 1992-05-06 Univ Leeds Artificial heart valve
US5713950A (en) 1993-11-01 1998-02-03 Cox; James L. Method of replacing heart valves using flexible tubes
US5509930A (en) 1993-12-17 1996-04-23 Autogenics Stentless heart valve
US5562729A (en) 1994-11-01 1996-10-08 Biocontrol Technology, Inc. Heart valve
DE19546692C2 (en) 1995-12-14 2002-11-07 Hans-Reiner Figulla Self-expanding heart valve prosthesis for implantation in the human body via a catheter system
US5855601A (en) 1996-06-21 1999-01-05 The Trustees Of Columbia University In The City Of New York Artificial heart valve and method and device for implanting the same
DE19624948A1 (en) 1996-06-24 1998-01-02 Adiam Medizintechnik Gmbh & Co Prosthetic heart valve
DE19625202A1 (en) * 1996-06-24 1998-01-02 Adiam Medizintechnik Gmbh & Co Prosthetic mitral heart valve
US6764509B2 (en) 1996-09-06 2004-07-20 Carbomedics Inc. Prosthetic heart valve with surface modification
US6206911B1 (en) 1996-12-19 2001-03-27 Simcha Milo Stent combination
EP0850607A1 (en) * 1996-12-31 1998-07-01 Cordis Corporation Valve prosthesis for implantation in body channels
GB9701479D0 (en) * 1997-01-24 1997-03-12 Aortech Europ Ltd Heart valve
US5957949A (en) 1997-05-01 1999-09-28 World Medical Manufacturing Corp. Percutaneous placement valve stent
US5855597A (en) 1997-05-07 1999-01-05 Iowa-India Investments Co. Limited Stent valve and stent graft for percutaneous surgery
US7452371B2 (en) 1999-06-02 2008-11-18 Cook Incorporated Implantable vascular device
US6117169A (en) 1998-06-24 2000-09-12 Sulzer Carbomedics Inc. Living hinge attachment of leaflet to a valve body
US6736845B2 (en) 1999-01-26 2004-05-18 Edwards Lifesciences Corporation Holder for flexible heart valve
US7628803B2 (en) 2001-02-05 2009-12-08 Cook Incorporated Implantable vascular device
US8382822B2 (en) 1999-06-02 2013-02-26 Cook Medical Technologies Llc Implantable vascular device
US6299637B1 (en) 1999-08-20 2001-10-09 Samuel M. Shaolian Transluminally implantable venous valve
US8016877B2 (en) 1999-11-17 2011-09-13 Medtronic Corevalve Llc Prosthetic valve for transluminal delivery
US8579966B2 (en) 1999-11-17 2013-11-12 Medtronic Corevalve Llc Prosthetic valve for transluminal delivery
US6458153B1 (en) 1999-12-31 2002-10-01 Abps Venture One, Ltd. Endoluminal cardiac and venous valve prostheses and methods of manufacture and delivery thereof
US7195641B2 (en) 1999-11-19 2007-03-27 Advanced Bio Prosthetic Surfaces, Ltd. Valvular prostheses having metal or pseudometallic construction and methods of manufacture
GB0114345D0 (en) 2001-06-13 2001-08-08 Aortech Europ Ltd Heart valve prosthesis and method of manufacture
US20030097175A1 (en) 1999-12-08 2003-05-22 O'connor Bernard Heart valve prosthesis and method of manufacture
GB9928905D0 (en) * 1999-12-08 2000-02-02 Aortech Europ Ltd Prosthesis
ATE399513T1 (en) 2000-01-27 2008-07-15 3F Therapeutics Inc HEART VALVE PROSTHESIS
US6454799B1 (en) * 2000-04-06 2002-09-24 Edwards Lifesciences Corporation Minimally-invasive heart valves and methods of use
US7510572B2 (en) 2000-09-12 2009-03-31 Shlomo Gabbay Implantation system for delivery of a heart valve prosthesis
US6482228B1 (en) 2000-11-14 2002-11-19 Troy R. Norred Percutaneous aortic valve replacement
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
US6454798B1 (en) 2000-12-21 2002-09-24 Sulzer Carbomedics Inc. Polymer heart valve with helical coaption surface
US6596024B2 (en) 2000-12-21 2003-07-22 Carbomedics Inc. Polymeric heart valve fabricated from polyurethane/polysiliconeurethane blends
WO2002074201A1 (en) 2001-03-16 2002-09-26 Mayo Foundation For Medical Education And Research Synthethic leaflets for heart valve repair or replacement
US7556646B2 (en) 2001-09-13 2009-07-07 Edwards Lifesciences Corporation Methods and apparatuses for deploying minimally-invasive heart valves
US6958076B2 (en) 2001-04-16 2005-10-25 Biomedical Research Associates Inc. Implantable venous valve
US7377938B2 (en) 2001-07-19 2008-05-27 The Cleveland Clinic Foundation Prosthetic cardiac value and method for making same
US6562069B2 (en) 2001-09-19 2003-05-13 St. Jude Medical, Inc. Polymer leaflet designs for medical devices
US6893460B2 (en) 2001-10-11 2005-05-17 Percutaneous Valve Technologies Inc. Implantable prosthetic valve
US20030114924A1 (en) 2001-12-18 2003-06-19 Riyad Moe Polymer heart valve
WO2003070124A2 (en) 2002-02-20 2003-08-28 Osse Francisco J Venous bi-valve
US6716241B2 (en) 2002-03-05 2004-04-06 John G. Wilder Venous valve and graft combination
US7125418B2 (en) 2002-04-16 2006-10-24 The International Heart Institute Of Montana Foundation Sigmoid valve and method for its percutaneous implantation
US7160320B2 (en) 2002-04-16 2007-01-09 The International Heart Institute Of Montana Foundation Reed valve for implantation into mammalian blood vessels and heart with optional temporary or permanent support
US8721713B2 (en) 2002-04-23 2014-05-13 Medtronic, Inc. System for implanting a replacement valve
US7041132B2 (en) 2002-08-16 2006-05-09 3F Therapeutics, Inc, Percutaneously delivered heart valve and delivery means thereof
GB2407146B (en) 2003-03-20 2006-04-26 Aortech Internat Plc Valve leaflet for use in cardiac valve prosthesis
DE602004023708D1 (en) 2003-04-24 2009-12-03 Cook Inc ARTIFICIAL FLAP FLAP WITH IMPROVED FLOW BEHAVIOR
US20050075724A1 (en) 2003-10-06 2005-04-07 Oleg Svanidze Minimally invasive valve replacement system
US7854761B2 (en) 2003-12-19 2010-12-21 Boston Scientific Scimed, Inc. Methods for venous valve replacement with a catheter
US8128681B2 (en) 2003-12-19 2012-03-06 Boston Scientific Scimed, Inc. Venous valve apparatus, system, and method
US7261732B2 (en) 2003-12-22 2007-08-28 Henri Justino Stent mounted valve
EP2529696B1 (en) 2003-12-23 2014-01-29 Sadra Medical, Inc. Repositionable heart valve
US7780725B2 (en) 2004-06-16 2010-08-24 Sadra Medical, Inc. Everting heart valve
US7959666B2 (en) 2003-12-23 2011-06-14 Sadra Medical, Inc. Methods and apparatus for endovascularly replacing a heart valve
US7329279B2 (en) 2003-12-23 2008-02-12 Sadra Medical, Inc. Methods and apparatus for endovascularly replacing a patient's heart valve
ITTO20040135A1 (en) 2004-03-03 2004-06-03 Sorin Biomedica Cardio Spa CARDIAC VALVE PROSTHESIS
US7445630B2 (en) 2004-05-05 2008-11-04 Direct Flow Medical, Inc. Method of in situ formation of translumenally deployable heart valve support
US20060122693A1 (en) * 2004-05-10 2006-06-08 Youssef Biadillah Stent valve and method of manufacturing same
WO2005118019A1 (en) 2004-05-28 2005-12-15 Cook Incorporated Implantable bioabsorbable valve support frame
US20060052867A1 (en) 2004-09-07 2006-03-09 Medtronic, Inc Replacement prosthetic heart valve, system and method of implant
WO2006086135A2 (en) 2005-01-21 2006-08-17 Innovia, Llc Stent-valve and deployment catheter for use therewith
ITTO20050074A1 (en) 2005-02-10 2006-08-11 Sorin Biomedica Cardio Srl CARDIAC VALVE PROSTHESIS
WO2006096449A2 (en) * 2005-03-03 2006-09-14 Hines Richard A Endovascular aneurysm treatment device and delivery system
US8012198B2 (en) 2005-06-10 2011-09-06 Boston Scientific Scimed, Inc. Venous valve, system, and method
WO2007016251A2 (en) 2005-07-28 2007-02-08 Cook Incorporated Implantable thromboresistant valve
US7455689B2 (en) 2005-08-25 2008-11-25 Edwards Lifesciences Corporation Four-leaflet stented mitral heart valve
US8470022B2 (en) 2005-08-31 2013-06-25 Cook Biotech Incorporated Implantable valve
US20070050013A1 (en) 2005-09-01 2007-03-01 Jeffrey M. Gross Venous valve prosthesis and method of fabrication
US7530253B2 (en) 2005-09-09 2009-05-12 Edwards Lifesciences Corporation Prosthetic valve crimping device
US7569071B2 (en) 2005-09-21 2009-08-04 Boston Scientific Scimed, Inc. Venous valve, system, and method with sinus pocket
WO2007038540A1 (en) 2005-09-26 2007-04-05 Medtronic, Inc. Prosthetic cardiac and venous valves
US20070213813A1 (en) 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
US7648527B2 (en) 2006-03-01 2010-01-19 Cook Incorporated Methods of reducing retrograde flow
US8219229B2 (en) 2006-03-02 2012-07-10 Edwards Lifesciences Corporation Virtual heart valve
US8038710B2 (en) 2006-05-30 2011-10-18 Cook Medical Technologies Llc Artificial valve prosthesis
ES2432558T3 (en) 2006-06-09 2013-12-04 Eidgenössische Technische Hochschule Zürich Supports for artificial heart valves and vascular structures
US8500799B2 (en) * 2006-06-20 2013-08-06 Cardiacmd, Inc. Prosthetic heart valves, support structures and systems and methods for implanting same
US8163011B2 (en) 2006-10-06 2012-04-24 BioStable Science & Engineering, Inc. Intra-annular mounting frame for aortic valve repair
WO2008046092A2 (en) * 2006-10-13 2008-04-17 Creighton University Implantable valve prosthesis
US7935144B2 (en) * 2006-10-19 2011-05-03 Direct Flow Medical, Inc. Profile reduction of valve implant
US9138315B2 (en) 2007-04-13 2015-09-22 Jenavalve Technology Gmbh Medical device for treating a heart valve insufficiency or stenosis
AU2008294012B2 (en) 2007-08-24 2013-04-18 St. Jude Medical, Inc. Prosthetic aortic heart valves
US20090062907A1 (en) 2007-08-31 2009-03-05 Quijano Rodolfo C Self-expanding valve for the venous system
US8454686B2 (en) 2007-09-28 2013-06-04 St. Jude Medical, Inc. Two-stage collapsible/expandable prosthetic heart valves and anchoring systems
US20090138079A1 (en) 2007-10-10 2009-05-28 Vector Technologies Ltd. Prosthetic heart valve for transfemoral delivery
US20090171456A1 (en) * 2007-12-28 2009-07-02 Kveen Graig L Percutaneous heart valve, system, and method
EP2254514B1 (en) 2008-01-24 2018-10-03 Medtronic, Inc Stents for prosthetic heart valves
WO2009094197A1 (en) 2008-01-24 2009-07-30 Medtronic, Inc. Stents for prosthetic heart valves
WO2009104041A1 (en) * 2008-02-21 2009-08-27 Valerian Voinov Implantable prosthetic valve stent
US8017396B2 (en) 2008-02-22 2011-09-13 Vijay Kumar Cellulose based heart valve prosthesis
US9241792B2 (en) 2008-02-29 2016-01-26 Edwards Lifesciences Corporation Two-step heart valve implantation
US8312825B2 (en) 2008-04-23 2012-11-20 Medtronic, Inc. Methods and apparatuses for assembly of a pericardial prosthetic heart valve
US9061119B2 (en) 2008-05-09 2015-06-23 Edwards Lifesciences Corporation Low profile delivery system for transcatheter heart valve
EP2119417B2 (en) 2008-05-16 2020-04-29 Sorin Group Italia S.r.l. Atraumatic prosthetic heart valve prosthesis
US9061464B2 (en) * 2008-09-03 2015-06-23 Collagen Matrix, Inc. Re-rollable wrapping implant
US9314335B2 (en) 2008-09-19 2016-04-19 Edwards Lifesciences Corporation Prosthetic heart valve configured to receive a percutaneous prosthetic heart valve implantation
US8137398B2 (en) 2008-10-13 2012-03-20 Medtronic Ventor Technologies Ltd Prosthetic valve having tapered tip when compressed for delivery
US9119714B2 (en) 2008-10-29 2015-09-01 The Regents Of The University Of Colorado, A Body Corporate Shape memory polymer prosthetic medical device
US8556960B2 (en) 2008-11-06 2013-10-15 Cook Medical Technologies Llc Frameless vascular valve
WO2010098857A1 (en) 2009-02-27 2010-09-02 St. Jude Medical, Inc. Stent features for collapsible prosthetic heart valves
US9980818B2 (en) 2009-03-31 2018-05-29 Edwards Lifesciences Corporation Prosthetic heart valve system with positioning markers
US8512397B2 (en) 2009-04-27 2013-08-20 Sorin Group Italia S.R.L. Prosthetic vascular conduit
WO2010129900A1 (en) * 2009-05-07 2010-11-11 Georgia Tech Research Corporation Implantable prosthetic vascular valves
US8075611B2 (en) 2009-06-02 2011-12-13 Medtronic, Inc. Stented prosthetic heart valves
EP4643824A2 (en) * 2009-12-08 2025-11-05 Avalon Medical Ltd. Device and system for transcatheter mitral valve replacement
US10512537B2 (en) 2010-04-16 2019-12-24 Abiomed, Inc. Flow optimized polymeric heart valve
US9833314B2 (en) * 2010-04-16 2017-12-05 Abiomed, Inc. Percutaneous valve deployment
RS60677B1 (en) 2010-10-05 2020-09-30 Edwards Lifesciences Corp Prosthetic heart valve
US8932343B2 (en) * 2011-02-01 2015-01-13 St. Jude Medical, Cardiology Division, Inc. Blunt ended stent for prosthetic heart valve
GB2488530A (en) * 2011-02-18 2012-09-05 David J Wheatley Heart valve
CA2842091A1 (en) 2011-07-20 2013-01-24 Boston Scientific Scimed, Inc. Prosthetic heart valve
EP2736453A1 (en) 2011-07-29 2014-06-04 St. Jude Medical, Inc. Dipping mandrel with a gap
US9827093B2 (en) * 2011-10-21 2017-11-28 Edwards Lifesciences Cardiaq Llc Actively controllable stent, stent graft, heart valve and method of controlling same
US9433991B2 (en) * 2011-12-21 2016-09-06 Edwards Lifesciences Corporation Apparatus and method for stent shaping
WO2013103612A1 (en) * 2012-01-04 2013-07-11 Tendyne Holdings, Inc. Improved multi-component cuff designs for transcatheter mitral valve replacement, subvalvular sealing apparatus for transcatheter mitral valves and wire framed leaflet assembly
US9642700B2 (en) * 2012-05-31 2017-05-09 St. Jude Medical, Cardiology Division, Inc. Prosthetic heart valve having a polymeric stent
EP2866847B1 (en) 2012-07-02 2018-08-22 Boston Scientific Scimed, Inc. Prosthetic heart valve formation
US10376360B2 (en) 2012-07-27 2019-08-13 W. L. Gore & Associates, Inc. Multi-frame prosthetic valve apparatus and methods
US20140107772A1 (en) 2012-10-12 2014-04-17 St. Jude Medical, Cardiology Division, Inc. Roughened cuff surface
BR112015026425B1 (en) * 2013-04-19 2021-11-23 Strait Access Technologies Holdings (Pty) Ltd HEART VALVE PROSTHESIS, STENT AND LEAFLET
JP6557217B2 (en) 2013-05-01 2019-08-07 アニュメド, インコーポレイテッド Personalized aortic valve prosthesis
WO2014209232A1 (en) 2013-06-25 2014-12-31 National University Of Singapore Stent member, artificial valve, and method of implanting the same
CA2910602C (en) 2013-09-20 2020-03-10 Edwards Lifesciences Corporation Heart valves with increased effective orifice area
US10478290B2 (en) 2013-11-26 2019-11-19 Children's Medical Center Corporation Expandable stent valve
WO2015169869A1 (en) 2014-05-06 2015-11-12 Dsm Ip Assets B.V. Method of making a prosthetic valve and valve obtained therewith
CA2948179C (en) 2014-05-07 2023-08-15 Baylor College Of Medicine Artificial, flexible valves and methods of fabricating and serially expanding the same
WO2015175524A1 (en) 2014-05-16 2015-11-19 St. Jude Medical, Cardiology Division, Inc. Subannular sealing for paravalvular leak protection
US9827094B2 (en) 2014-09-15 2017-11-28 W. L. Gore & Associates, Inc. Prosthetic heart valve with retention elements
US10869755B2 (en) 2014-12-09 2020-12-22 Cephea Valve Technologies, Inc. Replacement cardiac valves and methods of use and manufacture
WO2018184225A1 (en) * 2017-04-07 2018-10-11 上海甲悦医疗器械有限公司 Artificial heart valve
EP3697345A1 (en) * 2017-10-23 2020-08-26 Symetis SA Prosthetic valve leaflet
US11202708B2 (en) * 2017-11-08 2021-12-21 The Charles Stark Draper Laboratory, Inc. Segmented, growth-accommodating, artificial valve
US11071626B2 (en) * 2018-03-16 2021-07-27 W. L. Gore & Associates, Inc. Diametric expansion features for prosthetic valves
US20210137676A1 (en) * 2019-11-08 2021-05-13 The Regents Of The University Of California Growth-accommodating valve system

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11464632B2 (en) 2014-05-07 2022-10-11 Baylor College Of Medicine Transcatheter and serially-expandable artificial heart valve
US11571300B2 (en) 2014-05-07 2023-02-07 Baylor College Of Medicine Serially expanding an artificial heart valve within a pediatric patient

Also Published As

Publication number Publication date
EP3139865B1 (en) 2025-07-16
US11464632B2 (en) 2022-10-11
US20170189175A1 (en) 2017-07-06
EP3139865A2 (en) 2017-03-15
US20220117731A1 (en) 2022-04-21
CA2948179A1 (en) 2015-11-12
WO2015171743A2 (en) 2015-11-12
WO2015171743A3 (en) 2015-12-17
US11571300B2 (en) 2023-02-07
CA2948179C (en) 2023-08-15
US20220125581A1 (en) 2022-04-28
EP3139865A4 (en) 2018-03-28
US20230135271A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
US11464632B2 (en) Transcatheter and serially-expandable artificial heart valve
JP7393005B2 (en) Replacement heart valve with fewer sutures
US9474609B2 (en) Venous valve, system, and method with sinus pocket
US9456898B2 (en) Heart valve prosthesis with open stent
EP2379322B1 (en) Synthetic composite structures
US10864094B2 (en) Fatigue-resistant flow regulating device and manufacturing methods
EP3266417A1 (en) Multi-frame prosthetic heart valve
EP3644905B1 (en) Tri-leaflet prosthetic heart valve
US20180168795A1 (en) Valved conduit and method for fabricating same
CN104661618A (en) valve
HK40106018A (en) Heart valve prosthesis with open stent

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION